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Relaxin, a hormone of pregnancy, has shown broad cardioprotective effects including 
anti-fibrotic (reversed excess TGFβ signaling), anti-arrhythmic (Nav1.5 and INa upregulation and 
Cx43 phosphorylation and trafficking to intercalated disks) and anti-inflammatory properties 
(reduced IL-1β and IL-6). While relaxin’s anti-fibrotic effects are thought to occur through the 
SMAD2/3/TGFβ pathway, there is a general lack of understanding of relaxin’s mode of action to 
increase sodium current and alter connexin43 localization to suppress arrhythmias. Based on a 
rat model of aging, we tested the hypothesis that relaxin acts through activation of Wnt/β-
catenin signaling to mediate its effects on Nav1.5 and Cx43 and to regulate collagen expression. 
We show for the first time that relaxin activates canonical Wnt signaling (increased nuclear β-
catenin) to increase Nav1.5 in isolated cardiomyocytes. Block of canonical Wnt signaling (via 
Dikkopf-1) abrogated relaxin’s effect on both Nav1.5 in cardiomyocytes and suppression of 
excess collagen from fibroblasts. Further, we show that relaxin significantly suppressed 
expression of Dikkopf-1 in isolated cardiomyocytes and whole LV tissue. In addition, show that 
relaxin suppressed the age-associated genetic upregulation in inflammatory markers in a sex-
dependent manner.  Finally, we tested the hypothesis that relaxin would be an effective therapy 
in a rat model of pulmonary arterial hypertension and show that it reduced occlusion of small 
pulmonary arteries, myocardial and lung fibrosis and reversed the cardiac phenotype of 
ventricular arrhythmia or arrest. These results suggest that relaxin signals through multiple 
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pathways to achieve its myriad effects and that relaxin has great potential as a therapy for 
multiple cardiopulmonary diseases. 
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1.0  Introduction 
1.1 Relaxin 
Relaxin (RLX) was first discovered by Frederick Hisaw in 1926, when he showed that 
injection of serum from pregnant guinea pigs into virgin guinea pigs resulted in relaxation of the 
pubic ligament.[1] The hormone was extracted from the corpus luteum of the pig in 1930 and 
was officially named RLX.[1] In subsequent years, RLX was shown to be structurally like 
insulin (53 a.a.), containing conserved cysteine residues, an A and a B chain and two inter- and 
one intra-chain disulfide bond.[1, 2, 3] Humans (and other primates) have three RLX genes 
(RLN1-3) encoding for RLX 1-3, though lower mammals (e.g., mice) have only RLN1 and 
RLN3. RLN1 in lower mammals is equivalent to RLN2 in humans and other primates and 
encode for the most prominent circulating RLX in the body (hence, RLX2 in humans and RLX1 
in rodents will be referred to herein as RLX). RLN3 encodes for RLX-3 which is primarily 
expressed in the brain of mammals.[1] Cloning techniques and database searches led to the 
discovery of several insulin-like peptides (INSL) 3-6, of which INSL-3 is expressed highly in 
Leydig cells and probably plays a role in testis descent in males and fertility in females, much 
less is known about INSL 4-6.[1] 
The primary RLX receptors are classified as the relaxin family peptide receptors (RXFP) 
1-4 and are G-protein coupled receptors (GPCR). RXFP1, the primary receptor for RLX, was 
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deorphanized in 2002 through recognition that RLX increased cAMP signaling, a mechanism 
prominently linked to GPCRs.[1, 3 4] In addition to a seven-transmembrane domain, a prominent 
feature of GPCRs, RXFP1 contains an extracellular leucine rich repeat domain connected to the 
transmembrane domain by a cysteine-rich hinge [2], and also contains a low-density lipoprotein 
receptor type A (LDLa) module connected to the LRR through a linker.[1] 
Activation of RXFP1 by RLX is thought to involve binding of the RLX B-chain to the 
LRR and interaction of the LDLa-LRR linker with the RLX A chain [1, 5] and exoloops of the 
transmembrane domains. In sum, the binding of RLX to RXFP1 involves complex interactions 
which makes it challenging to develop RLX mimetics RLX was extensively studied as a 
hormone of pregnancy and was found to play a critical role in several aspects of the reproductive 
process; to name a few: a) softening of the birth canal, probably due to its regulation of the 
extracellular matrix components, b) decidualization, c) implantation, d) suppression of uterine 
contractions e) regulation of nipple development, increased maternal renal plasma flow, 
glomerular filtration, and cardiac output.[6, 7] Finally, it should be noted that RLX and RXFP1 
expression and localization vary as a function of species and sex [1], and may have gender 
specific roles during inflammation.[8]  
There is a growing body of evidence that indicates a still broader range of actions by 
RLX beyond those of reproduction. For instance, its receptor, RXFP1 has been found to be 
expressed in a myriad of tissues and organs including ovaries, mammary glands, testis, prostate, 
brain, liver, kidney, lung, vasculature and heart.[1, 9, 10] Moreover, exogenously added RLX 
appears to exert positive/beneficial genomic effects in many of these organs.[8, 11, 12, 14, 15] In 
clinical trials, RLX was well tolerated with no adverse effects in heart failure patients.[16] 
Interestingly, serum RLX levels are increased in patients (males and females) with particular 
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diseases: prostate cancer [17], pulmonary arterial hypertension [18], atrial fibrillation and heart 
failure. Many of these pathologies are associated with a common set of risk factors (e.g. age, 
hypertension, myocardial ischemia, fibrosis and inflammation).[19, 20, 21] It is important to note 
that there is a significant controversy regarding he accuracy and validity of commercially 
available RLX assay kits which casts doubt on the interpretation of the data and some of these 
studies will have to be revisited with new assays that detect RLX concentrations more 
reliably.[22] 
As shown by Debrah et al, [23, 24, 25] RLX treatment resulted in marked cardiovascular 
effects: increased cardiac output and arterial compliance, decreased arterial load, reduced 
collagen expression and beneficial remodeling of the vascular wall.  
The primary goal of this introduction is to give an overview of RLX-mediated 
cardioprotective actions and will only touch briefly on RLX effects in other organs. However, a 
discussion of RLX’s signaling mechanisms will be centered on findings in neonatal and non-
cardiac cells, since little work has been done in adult primary cardiac cells, a deficit that our lab 
is trying to remedy. The review will include a discussion of RLX’s signaling mechanisms in 
fibroblasts and myocytes, its anti-arrhythmic properties, and anti-inflammatory properties. The 
review will also present a brief history of RLX’s use in clinical trials for patients with acute 
decompensated heart failure and recent attempts at developing RLX mimetics. 
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1.2 Relaxin As an Anti-fibrotic 
In response to injury or disease, inflammatory cells are recruited to the site of injury for 
tissue repair, wound closure or pathogen removal. Pro-fibrotic and inflammatory cytokine levels 
(e.g. TGFβ1, Angiotensin II) are increased and activate fibroblasts to their collagen secreting 
phenotype, the myofibroblast.[26] The inability of the body to resolve the injury or remove the 
source of infection can cause prolonged activation of fibroblasts resulting in pathological 
collagen accumulation and myocardial stiffness, impaired systolic and diastolic function and 
increased arrhythmogenicity. Atrial and ventricular fibrosis may increase the arrhythmia risk due 
to a direct increase in extracellular resistance and an increase in the tortuosity of the extracellular 
matrix. 
Based on mathematical simulations the effects of fibrosis on conduction velocity are not 
significant if based on changes in extracellular resistance or extracellular tortuosity.[27] A more 
significantly effect comes about from the trans-differentiation of fibroblasts to myofibroblasts as 
the latter express connexin 43 which may form gap-junctions between myofibroblasts and 
myocytes. Such heterotypic junctions would tend to depolarize the resting potential of myocytes, 
slow-down the action potential upstroke and conduction velocity of the action potential, resulting 
in reentrant electrical circuits. Such heterotypic cell-cell coupling could be demonstrated in co-
cultures of fibroblasts and myocytes [28] but direct evidence of their occurrence in an infarct was 
lacking. A more recent study demonstrated that in mice with a cryoablated infarct, myocytes 
formed heterotypic junctions with cells in the myocardial scar.[29] While fibrosis promotes 
arrhythmia, [30] an important question is what promotes pathological fibrosis. Several factors 
have been associated with increases in fibrosis: increased cardiac afterload, cell death or cell 
stretching can lead to release of pro-fibrotic cytokines from cardiomyocytes and fibroblasts, 
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resulting in fibroblast activation and pathological collagen deposition.[31] In addition, fibrosis 
can also be idiopathic with no known instigating trigger.[32] 
In addition to the pro-fibrotic cytokines TGFβ and Ang II, Wnt signaling has emerged as 
a player in fibroblast activation and fibrosis. In the absence of canonical Wnt ligands, cytosolic 
β-catenin is phosphorylated and marked for ubiquitination by the destruction complex 
comprising GSK3β, Adenomatosis Polyposis Coli, casein kinase 1 and Axin. During canonical 
Wnt signaling, Wnt ligands bind to frizzled receptors and co-receptors, lipoprotein receptor-
related protein (LRP) 5/6, which leads to disassembly of the destruction complex, and 
translocation of β-catenin into the nucleus, where it acts as a co-transcription factor with TCF 
and LEF.[33] Canonical Wnt signaling has multiple native inhibitors, the Dickkopf (DKK) 1-4 
proteins, the secreted frizzled related proteins (sFRP) 1-5 and Wnt inhibitor factor (WIF)-1.[34] 
Studies have shown that canonical Wnt signaling in fibroblasts results in increased collagen 
expression in human and mouse dermal fibroblasts through increased Wnt1 and decreased DKK1 
expression.[32] Similarly, He et al [35] showed that addition of sFRP2 resulted in reduced 
collagen production by cardiac fibroblasts in 6-week old Sprague Dawley rats, while Kobayashi 
et al [36] report that sFRP2 results in increased collagen and that sFRP2 null mice show less 
fibrotic scar after MI. These conflicting sFRP2 results can partially be reconciled in that sFRP2 
appears to exhibit a biphasic response and that at low concentrations, as used in the Kobayashi 
report, sFRP2 is pro-fibrotic and at higher doses, such as used in the He study, sFRP appears to 
be anti-fibrotic. Further, Blyszczuk et al [37] showed in a model of experimental autoimmune 
myocarditis, that inflammatory CD133+ cells convert to myofibroblasts in the presence of TGFβ, 
and that this effect is dependent on active Wnt signaling. They showed that inhibition of Wnt 
signaling via high dose of sFRP2 blocks activation of fibroblasts, though they do not show 
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results with low dose sFRP2. In sum, Wnt signaling appears to be intricately involved in 
fibroblast activation, collagen secretion and pathological fibrosis, though further work exploring 
dose dependence and time-course treatments should be performed to better understand the 
interplay between TGFβ and Wnt signaling.  
Fibrosis is a common component of many cardiovascular diseases including hypertension 
[11, 14], myocardial infarction [38], cardiac arrhythmogenesis [13, 14] and normal, ‘healthy’ 
aging.[8, 39] More recently, RLX has emerged as a potent antifibrotic in cardiac tissue and 
isolated fibroblasts, as numerous studies showed that RLX reverses cardiac fibrosis in 
hypertensive, arrhythmogenic and aged rats [11, 13, 14, 40], as well as diabetic cardiomyopathy 
[41] and myocardial infarction.[38]. In agreement with these findings, RLX-/- mice develop 
multi-organ fibrosis at an early age compared to RLX+/+ mice, although cardiac fibrosis is sex-
dependent, being pronounced in RLX-/- male but not female mice.[42] 
As mentioned, fibroblast activation is characterized by increased stress fiber formation 
and elevated α-smooth muscle actin and collagen expression, a process shown to be inhibited by 
RLX.[43] Pioneering studies by Unemori and Amento in dermal [44] and lung fibroblasts 
showed that RLX (10 and 100 ng/mL)significantly increased the expression of pro-collagenase 
and decreased expression of the procollagenase inhibitor, the tissue inhibitor of 
metalloproteinases (TIMP), and the expression of collagen mRNA and protein. Further work by 
Palejwala et al [45, 46], using human lower segment uterine fibroblasts from full-term women 
confirmed the effects of RLX (1 and 10 ng/mL) on pro-collagenase expression and an increase in 
MMP-2 and MMP-3, while downregulating TIMP-1. Interestingly, they showed that RLX 
significantly increased protein tyrosine phosphorylation and that RLX mediated effects on 
MMP-1 and MMP-3 were c-Raf (serine/threonine kinase) dependent.  
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Studies in recent years have led to partial elucidation of the mechanism by which RLX 
blocks fibroblast activation and collagen secretion. Samuel et al [43] showed that cardiac 
fibroblasts from 1-day old Sprague Dawley (SD) rats treated with TGFβ1 (1-2 ng/mL) or 
Angiotensin II (Ang II, 1-5X10-7 M) for 72-hours resulted in a significant increase in collagen 
expression in atrial and ventricular fibroblasts that was inhibited by RLX (100 ng/mL). In 
addition, they showed that Ang II stimulated fibroblast proliferation was significantly blocked by 
RLX treatment. 
RLX did not significantly alter baseline levels of collagen yet suppressed pathological 
collagen, suggesting that RLX blocks the action of certain cytokines that activate fibroblasts 
rather than altering collagen expression directly. Nevertheless, male 12-month-old RLX-/- mice 
exhibit significantly higher levels of ventricular fibrosis compared to littermate controls, and 
RLX treatment (500 μg/kg/day for 2-weeks) significantly reduced collagen accumulation 
(Samuel et al., 2004). Based on a cAMP bioassay, there was no correlation between RLX-
dependent suppression of fibrosis and cAMP levels in fibroblasts suggesting that RLX regulation 
of fibrosis was not mediated by an increase in cAMP.[43] RLX’s anti-fibrotic mechanism was 
elucidated further in a study by Heeg et al [47] using two renal fibroblast cell lines. They showed 
that RLXs anti-fibrotic properties are mediated through an inhibition of TGFβ, and an inhibition 
of SMAD2 phosphorylation and nuclear translocation. Mookerjee et al [48] confirmed the effects 
seen by Heeg et al and showed that inhibition of nitric oxide (NO) signaling, primarily nNOS 
and cGMP, significantly abrogated RLX’s anti-fibrotic effects. Sassoli et al [49] expanded these 
studies by showing that in NIH/3T3 fibroblasts, and in fibroblasts isolated from 1-day old CD1 
albino mice, TGFβ reduced the expression of the Notch-1 receptor and its ligand, Jagged-1, and 
both effects were reversed by RLX. RLX significantly decreased SMAD3 phosphorylation and 
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inhibition of Notch signaling increased pSMAD3 and abrogated RLXs effect. Similar findings 
were observed in human umbilical vascular endothelial cells where inhibition of Notch-signaling 
significantly blocked the effects of RLX on cell migration and endothelial-mesenchymal 
transition (EndoMT).[50] 
Besides fibrosis, activation of fibroblasts can result in the expression of ionic channels 
and currents.[51] The electrical properties of activated fibroblast may have significant 
consequences on cardiac arrhythmias because these fibroblasts may couple electrically with 
neighboring cardiomyocytes via functional gap junctions [52, 53], depolarize these 
cardiomyocytes and alter their electrical activity.[55] A study by Li et al [56] showed that small 
percentages of human cardiac fibroblasts exhibit K+, Cl- and Na+ currents, but do not mention if 
expression of ionic currents correlated with normal fibroblasts or with myofibroblasts. Chatelier 
et al [57] and Koivumaki et al [58], suggest that Na+ channel proteins and Na+ currents are 
measurable in myofibroblasts but not in fibroblasts. Squecco et al [51] showed that compared to 
control, TGFβ treated fibroblasts had significantly lower (more negative) resting membrane 
potentials and increased delayed rectifier K+ current (IKDR). In addition, TGFβ increased the 
Ca2+ dependent K+ current (IBK), the inward rectifying K+ current (IKir) and the slow 
component of the delayed rectifier K+ current (IKs) compared to untreated controls. RLX 
significantly blocked TGFβ-induced increases in each of these currents, suggesting that RLXs 
anti-fibrotic effects may involve inhibition of fibroblast activation by blocking ion channel 
expression and current. Further work suggests that RLX blocks TGFβ-mediated STAT3 
phosphorylation and autophagy [59], and may signal through PKCδ to mediate its effects in 
diabetic cardiomyopathy.[60] The inhibitory mechanisms of RLX on fibroblast activation are 
summarized in Table 1 and Figure 1. 
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Table 1: Mechanisms of Collagen Inhibition by Relaxin. 
Fibroblast Source RLX Anti-Fibrotic Effect RLX Mechanism in Fibroblast References 
Dermal Fibroblasts (human) 
Lung Fibroblast (adult 
human) 
↓TGFβ mediated collagen and 
fibronectin expression 
↓TIMP 
↑MMP-1 
 
N/A 
Unemori and Amento. 1990; 
Unemori, et al, 1996 
Lower Uterine Segment 
Fibroblasts (full-term human) 
↓TIMP 
↑MMP-1, MMP-2, MMP-3 
Tyrosine Phosphorylation 
c-Raf dependent 
PKC and cAMP independent 
 
Palejwala et al. 2001 
Cardiac Fibroblasts (1-day 
old, SD Rat) 
↓TGFβ/Ang II mediated collagen 
secretion 
↓Autophagy 
No change in cAMP 
↓STAT3 phosphorylation and 
autophagy 
↑PKCδ expression 
 
Samuel et al. 2004; Yuan et 
al. 2017; Wang et al. 2017 
TK-173, TK188 Renal 
Fibroblast Cell Lines 
↓TGFβ-mediated fibroblast 
differentiation (↓αSMA) 
↓Collagen expression 
↑MMP-2/9 
↑Tyrosine phosphorylation 
TGFβ receptor binding in unaffected 
↓SMAD2 phosphorylation 
↓SMAD2 nuclear translocation 
No effect on SMAD3/7 translocation 
MAP kinases (JNK1/2, ERK and 
p38) phosphorylation unaffected 
 
Heeg et al. 2005 
Primary Renal Cortical 
Fibroblasts (3-days post 
unilateral ureteric 
obstruction) 
↓fibroblast differentiation 
(↓αSMA) 
RXFP1 necessary for anti-fibrotic 
effect 
↓SMAD2 phosphorylation 
↑ERK1/2 phosphorylation 
RLX signals through nNOS-NO-
cGMP 
↓SMAD2 phosphorylation blocked 
by inhibition of nNOS or cGMP. 
 
Mookerjee et al. 2009 
NIH/3T3 and CD1 albino 
mouse (1-day old) 
↓Stress fiber formation 
↓Fibroblast differentiation 
(↓αSMA) 
↓TGFβ mediated collagen 
secretion 
↑MMP-2/9 
↓TIMP2 
Notch signaling negatively regulates 
TGFβ/SMAD3 
↓Notch Signaling by TGFβ 
↑Notch signaling by RLX 
↓K+ currents by RLX 
Sassoli et al. 2013; Squecco et 
al. 2015 
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Note that the studies outlined above were performed with non-cardiac fibroblasts, or 
neonate cardiac fibroblasts, and none studied RLX’s effect on adult cardiac fibroblasts. It is 
therefore unclear that the results seen in neonates or immortalized cell lines will translate to adult 
cardiac cells, and further work should be performed in this area. 
 
 
Figure 1: Relaxin Signaling Pathways in Fibroblasts. Collagen suppressing actions of Relaxin in fibroblasts. Relaxin inhibits TGFβ induced 
collagen overexpression through inhibition of SMAD2 phosphorylation and activation of the Notch signaling pathway. Further, relaxin has been 
shown to increase matrix metalloproteinase (MMP) expression to cleave big Endothelin (ET) to ET1-32, leading to increased nitric oxide (NO) 
signaling and suppressing collagen expression. Inhibition of NO signaling has been shown to significantly impede relaxin’s collagen suppressive 
effects. RLX: relaxin. RXFP1: relaxin family peptide receptor 1. LRR: leucine rich repeat. LDLa: low density lipoprotein A module. NICD: 
activated intracellular Notch-1; TIMP. Tissue inhibitor of metalloproteinase. 
 
1.3 Relaxin As an Anti-Arrhythmic 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, increases with age and is 
characterized by uncoordinated contractions of the atria, resulting in blood clot formation and 
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stroke[13, 14, 62]During normal sinus rhythm, the pacemaker action potential is initiated in the 
sinoatrial (SA) node, propagates across the right and left atria, is delayed at the atrioventricular 
node, and propagates through the specialized conduction system then throughout the right and 
left ventricles. In each cell, the action potential controls the myocyte contraction and except for 
SA nodal cells, normal, healthy myocytes do not fire action potentials spontaneously.[62] 
Supraventricular arrhythmias, like atrial fibrillation, impede ventricular contractions and ejection 
fraction slightly but result in a high-risk for stroke, and if untreated increase the vulnerability to 
heart failure. Electrical (e.g. ion channel expression) and structural (e.g. extracellular matrix) 
remodeling in aging, AF and HF alter the cardiac substrate and promote spontaneous APs that 
are out-of-phase with the intrinsic beat controlled by the SA node. Extra or premature APs can 
propagate as they encounter excitable tissue created by anatomical (MI) and/or dynamic blocks 
due to gradients of repolarization. These conditions lead to triggered activity and reentrant 
circuits that sustain fibrillation. Several factors can initiate arrhythmias [63] including 
spontaneous Ca2+ release from the sarcoplasmic reticulum resulting in delayed after 
depolarizations, [64, 65] through hyper-phosphorylation of ryanodine receptors by protein kinase 
A (PKA) [66] or Ca/calmodulin-dependent kinase II [67, 68], AP prolongation via increased 
Ca2+ influx and decreased K+ currents [69, 70], gap junction remodeling and reduced sodium 
current (INa) causing reduced AP conduction velocity (CV) [63, 71, 72], and cardiac fibrosis 
resulting in AP conduction block.[62] 
The first studies looking at RLXs effects on cardiac electrophysiology came from 
observations of RLXs chronotropic and ionotropic effects.[73] Han et al [73] used isolated cells 
from rabbit sinoatrial pacemaker cells to show that RLX (80 nmol/L) caused a significant 
increase in ICa,L in a PKA dependent manner. 
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In two studies of rat atrial cell electrophysiology, Piedras-Renteria et al [74, 75] showed 
that RLX (100 ng/mL) acutely inhibited the transient outward potassium current (ITO) in a PKA 
dependent manner causing a prolongation of AP duration (APD) and stronger contractions 
presumably due to an increase of Ca2+ influx due to the prolonged APD. 
Spontaneously hypertensive rats (SHR) are known to have a high susceptibility to AF 
than normotensive controls; Parikh et al [14] showed that RLX (500 μg/kg/day) dramatically 
reduced AF susceptibility in SHR hearts. They demonstrated that the interplay of several 
mechanisms mediated by RLX contributed to AF suppression, including: decreases in fibrosis 
and cellular hypertrophy and increased conduction velocity (CV) through an increase in voltage-
gated Na+ current, INa and Connexin 43 phosphorylation. Henry et al [13] extended these 
findings to aged rat hearts (F-344 Brown/Norway rats). In isolated cardiac myocytes derived 
from human induced pluripotent stem cells (hiPS-CMs), Parikh et al showed that RLX increased 
INa after 24 hours, and Henry et al obtained a similar result in adult rat atrial myocytes under 
voltage-clamp. The higher INa was associated with an increase in SCN5A (gene coding for 
Nav1.5) mRNA and Nav1.5, the primary subunit of the voltage-gated sodium channel protein, 
suggesting that RLX acted via a genomic mechanism rather than a post-translational 
modification of activation/inactivation kinetics of the Na+ channel. In aged rats, this hypothesis 
was strengthened by RNA-sequencing data [8] showing reduced SCN5A in aging and increased 
SCN5A expression by RLX in male and female LV [8] (GSE106377). Many of these findings 
have been confirmed in two studies in a murine myocardial infarction (MI) model [76, 77] 
showing a significant reduction in AF by RLX (75 μg/kg/day) after MI compared to control 
mice, significantly reduced fibrosis in the RLX group and reduced inflammatory markers In a rat 
model of MI, Wang et al [78] showed that RLX (500 μg/kg/day) significantly blunted the 
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reduction of Cx43 in the infarcted myocardium and suppressed ventricular tachyarrhythmia. 
Studies by Bani et al [79] and Nistri et al [80] showed in a rat and swine model of ischemia-
reperfusion (I/R) injury, respectively, that RLX (200 ng/ml [79] and 2 or 5 μg/kg/body weight 
[80]) significantly blocked cardiac mast cell activation, histamine release, neutrophil 
accumulation and reduced oxidative damage. They hypothesize these effects may have 
contributed to the anti-arrhythmic properties of RLX noted in these I/R models. 
 While we have shown that RLX significantly increased Nav1.5 expression, INa, and Cx43 
phosphorylation, the mechanisms underlying these effects remain unknown. A body of recent 
work suggests that Wnt signaling may play a pivotal role in ion channel and gap junction protein 
expression and ionic current regulation. Using NRVM cultured with Wnt1 or Wnt4, Ai et al [81] 
showed that Wnt1 significantly increased Cx43 protein and mRNA and β-catenin protein, while 
Wnt4 increased only Cx43 protein expression, having no effect on Cx43 mRNA or β-catenin 
protein. 
Work from Liang et al [82] showed that NRVM stimulated with Wnt3a or the Wnt 
signaling activator, CHIR-99021 (GSK3β inhibitor), resulted in a significant decrease in SCN5a 
mRNA expression (gene encoding Nav1.5), Nav1.5 protein and INa. Interestingly, Kir2.1 mRNA, 
protein and current were not affected by Wnt3a, nor were currents through L-type Ca2+ 
channels, or their associated mRNA or protein. The effect of Wnt signaling on Nav1.5 and INa is 
not certain; however, Asimaki et al [83] showed that activation of canonical Wnt signaling 
(inhibition of GSK3β with SB216763) prevented reduction of INa and IK1, and normalized 
expression and localization of the intercalated disk (ID) proteins plakoglobin and Cx43, in 
zebrafish and NRVM models of arrhythmogenic cardiomyopathy (ACM). These latter findings 
parallel the phenotype of ACM patients [83]. Murine models of ACM at age 3-weeks and 6- 
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months, treated with SB216763 showed marked improvement in fibrosis, inflammation and 
apoptosis, as well as protection from ventricular ectopy and increased levels of plakoglobin and 
Cx43 at IDs compared to non-treated ACM mice.[84] 
Ongoing work in our lab suggests that a close interplay between RLX and Wnt/βcatenin 
signaling accounts for the higher expression of Nav1.5 and Cx43 trafficking to the ID in adult (9- 
months) and aged (24-months) rat hearts. 
1.4 Relaxin Signaling Pathways 
GPCR-cAMP: Early studies proposed that the RLX receptor could be a tyrosine kinase 
receptor, due to its effects on protein tyrosine phosphorylation and cAMP accumulation.[46, 85, 
86] Hsu et al [3] first reported the leucine rich GPCRs LGR7 (RXFP1) and LGR8 (RXFP2) as 
the primary RLX receptors. Using 293T cells, they showed that RLX caused this rise in cAMP 
only when the cells were transfected with LGR7 or LGR8, and further showed that these 
receptors were present in brain, uterus, ovaries, prostate and the heart, among other organs. Early 
studies by Nguyen et al [87, 88] showed that RLX increased cAMP accumulation in a biphasic 
manner; the early increase in cAMP (1-2 minutes) is probably due to Gαs activation, and a later 
(10-20 minutes) rise in cAMP was due to phosphoinositide 3-kinase (PI3K) actions on PKCζ. 
Halls et al expanded this model to show that the G-βγ subunit was involved in the delayed 
activation of PI3K-PKC activity in RXFP1 expressing cells, but not RXFP2 cells.[89] It has been 
proposed that the RLX-cAMP signaling pathway differs at low RLX concentrations (attomolar 
vs. nanomolar) normally found in the blood, and involves a signalosome including AKAP97, 
PKA, PDE4D3 and β-arrestin-2.[90] Moreover, RLX signaling is cell dependent; for example, 
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cAMP does not appear to be involved in RLX mediated fibroblast signaling compared to other 
cell types studied (e.g. HUVSMC, HEK-293T).[89, 91] Further different cell types exhibit 
different cAMP responses to RLX and these responses as a function of RLX-dose can be bell-
shaped, or sigmoidal shaped responses.[91] A further complexity of RLX signaling is that RLX 
signaling differs in various cell types because it is dependent on the various combinations of 
different G proteins in a particular cell.[92, 93] In sum, RLX signaling through GPCRs is highly 
complex, dependent on cell type and organ specific. 
Nitric Oxide and Inflammation: Studies have shown that RLX increases coronary 
blood flow, is potent vasodilator, and that the nitric oxide (NO)-guanylyl cyclase-cGMP pathway 
is necessary for various actions of RLX.[94, 95]. Inhibition of NO signaling in a guinea pig 
model of ischemia-reperfusion and rat and guinea pig mast cells, blocked RLXs beneficial 
effects on coronary flow, NO production, histamine release, cell damage due to oxidative stress 
and cardiac contractions.[95, 96]. In bovine aortic smooth muscle cells, RLX was shown to 
increase inducible nitric oxide synthase (iNOS), cGMP and reduce intracellular calcium 
concentration.[97]. In addition, inhibition of NF-κB inhibited RLXs effect on NOS 
expression.[98] RLX blunted the adhesive nature of neutrophils to rat coronary endothelial cells 
through an NO-dependent mechanism by reducing the adhesion molecules P-selectin and 
VCAM-1, an effect blocked by NO inhibition [99] and RLX blocked the activation and 
migration of human neutrophils, and reduced superoxide anion expression in an NO dependent 
manner.[100]. RLX reduced ET-1 expression, increased the ETB receptor, and cleaved big ET to 
ET1-32 via a MMP-2 and MMP-9 dependent mechanism, which can activate NO signaling.[101] 
In addition, RLX increased the ETB receptor in a cell specific manner (e.g. endothelial and 
epithelial cells, but not smooth muscle cells) [102], though these findings of RLX on ETB 
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expression have been challenged.[103] NO has also been implicated in RLX-mediated inhibition 
of collagen secretion [48] through reductions in TGFβ signaling and inhibition of fibroblast to 
myofibroblast transition and increase MMP activity through and nNOS-NO mechanism.[78, 104] 
Not long after the discovery of RXFP1 and RXFP2 as RLX receptors by Hsu et al [3], it 
was shown by Dschietzig et al [105] that RLX can signal through the glucocorticoid receptor 
(GR) to blunt the secretion of pro-inflammatory cytokines in an RXFP independent 
manner.[106] They showed that endotoxin stimulated THP-1 monocytes treated with RLX (5-10 
nmol/L) secreted significantly less IL-1, IL-6 and TNFα, a response that was significantly 
reduced by the GR antagonist, RU-486. Moreover, since the medium was steroid free, they 
suggested that RLX interacts with the GR signaling pathway independently of any endogenous 
glucocorticoid steroids. RLX can blunt the NLRP3 inflammasome formation after ischemia and 
reperfusion via an endothelial NOS (eNOS) mechanism [107], and blocks neutrophil adhesion in 
rat coronary endothelial cells in an NO dependent fashion.[99]. Finally, we have shown that 
RLX can reverse the age associated inflammatory response in aged F-344 Brown/Norway rats 
through inhibition of various inflammatory pathways and antigen presentation, and that RLX 
blocks macrophage accumulation in the aged LV, and that these effects are sex-dependent.[8] 
1.5 Relaxin and Heart Failure 
Due to its proven vasodilatory properties, RLX has shown promise in treating patients with heart 
Failure.[108] A recent review has succinctly outlined the recent clinical trials involving the 
human recombinant form of RLX, termed Serelaxin [108], and will therefore be considered only 
briefly here. Early RLX experiments in human trials were interested in safety and tolerability of 
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RLX treatment, and Dschietzig et al [16] showed no serious adverse effects of RLX treatment 
delivered intravenously (IV) for 24 hours in concentrations up to 960 μg/kg/day in 16 patients, 
resulting in increased cardiac output, cardiac index, and reduced systemic vascular resistance and 
NT-pro-BNP. These effects lasted for at least 8 hours post-infusion. A phase II RLX study of 
more than 230 patients received RLX at 10, 30, 100 and 250 μg/kg/day, IV for 48-hours.[109] 
The study showed the greatest benefits at 30 μg/kg/day in length of hospital stay, worsening 
heart failure, dyspnea relief, 60-day readmission and 180-day cardiovascular mortality. 
Interestingly, in this study, patients receiving 250 μg/kg/day RLX began to show impaired renal 
function. Based on these studies, a larger phase III trial chose to use 30 μg/kg/day dosing to 
study the effects of RLX in acute heart failure in over 1100 heart failure patients.[110] This 
phase III study showed comparable results seen in phase II trial, though interestingly, showed no 
benefit in 60-day readmission seen in the phase II trial, but did show reduction in 180-day all-
cause mortality. Notably, in both the phase II and III trials, RLX led to a drop in systolic blood 
pressure that led to either stop of treatment or dose readjustment in some patients. Multiple post-
hoc analyses have been performed to understand which subgroups of patients benefit most from 
RLX treatment. Metra et al [111] suggests that the greatest benefits are seen in reduced 
cardiovascular events associated with age (>75 years), lymphocytes at baseline, glomerular 
filtration rate at baseline, hospital stay in the past year for heart failure and use of beta-blockers. 
Felker et al [112] showed that RLX had the greatest benefit by reducing cardiovascular deaths 
not associated with heart failure including reduced sudden cardiac death and stroke. Importantly, 
Filippatos et al [113] looked at the effects of RLX on the subgroups of heart failure with reduced 
ejection fraction compared to heart failure with preserved ejection fraction, for which no 
clinically effective therapy exists. RLX showed no difference in efficacy between the groups on 
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improved dyspnea up to 5 days post treatment, heart or renal failure at day 60 and cardiovascular 
death up to 180-days. 
In contrast to these results, a recent phase III clinical trial in acute heart failure showed no 
180-day benefit compared to placebo (www.Novarits.com, March 2017). Much has been made 
of this failed clinical trial as well as criticism of treating heart failure, a chronic disease, with 
acute therapies. 
McCullough [114] summarizes heart failure clinical trials within the past 15 years with 
similar treatment durations as the RLX trials and shows that these trials failed to meet their 
primary endpoints. He contends that a 48-hour treatment is unlikely to resolve phenotypes of 
heart failure which have been acting to alter organ and tissue substrates for an unspecified 
amount of time but in the range of years, and that, in contrast to quick hemodynamic 
improvements from drug therapies, adaptations at the organ and tissue level take longer to 
reverse, rendering short-term treatments likely to fail in long-term endpoints. 
It seems clear that RLX has potential to be a therapy for heart failure patients, yet no 
studies have been performed to determine the long-term effects of its anti-fibrotic or anti-
arrhythmic properties, nor have there been studies to determine repeat dosing strategies to obtain 
the greatest benefit. 
1.6 Relaxin Mimetics 
As detailed above, RLX has shown diverse protective effects on the cardiovascular and 
other organ systems. However, the full-chain RLX is costly to make, and has normally been 
associated with a short half-life (0.5-4 hrs) [22] in the blood.[115] Recent work has therefore led 
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to the development of RLX mimetics to obtain the beneficial anti-fibrotic characteristics of RLX 
by more economical means with potentially longer-lasting effects. Once such molecule is 
comprised only of residues 7-33 of the B-chain of RLX (B7-33).[116] B7-33 was shown to have 
a suppressed effect on cAMP compared to RLX, but increased phosphorylation of ERK1/2 and 
expression of MMP-2 in myofibroblasts to a level comparable to RLX. In addition, B7-33 
reduced collagen expression due to myocardial infarction or isoproterenol, and decreased lung 
fibrosis due to ovalbumin. A further study of B7-33 showed the mimetics ability to replicate 
RLXs effects in mesenteric arteries and to prevent endothelial dysfunction.[117] 
The small molecule, ML290, has been described as an RXFP1 agonist, resulting in 
increased cAMP levels and reduced collagen I gene expression in chronic liver disease.[118] In 
addition, ML290 has been shown to have similar signaling responses as RLX (e.g. increased 
cAMP through certain G-coupled proteins, p38MAPK, MMP-2, pSMAD2 and cGMP), while 
they differed in active p-ERK1/2 levels, though, interestingly, priming with ML290 enhanced 
RLXs effect on active p-ERK1/2. Moreover, ML290 did not appear to compete with RLX for 
RXFP1 binding suggesting an allosteric mechanism of action. ML290 appears to be an RXPF1 
agonist in humans, monkey’s and pigs, and an antagonist in mice, suggesting species bias in 
ML290 signaling.[118, 119, 120] However, studies with mouse RXFP1 replaced with humanized 
RXFP1 have shown that animal models can be developed to study the effects of ML290 in 
smaller rodents.[121] In contrast to RLX, ML290 has been shown to have a half-life in the heart 
and plasma of ~8 hours, opening the possibility of longer lasting effects with less treatment 
time.[119] An apparent limitation of RLX studies is the wide range of reported RLX half-life 
values in the plasma (reported from 10 minutes to 7-8 hours).[22, 119, 122] Duration or method 
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of administration, and whether RLX concentrations reach steady state in the blood may be a 
determinant and should be monitored closely. 
In sum, these data provide compelling evidence that RLX mimetics can re-create many of 
the positive effects of RLX with quicker production times and lower cost, and thus, while more 
testing is vital, suggest alternative RLX therapies for myriad of cardiovascular, renal, lung and 
other organ diseases. 
1.7 Introduction Conclusion 
Relaxin (RLX) is a hormone of pregnancy with a pleiotropy of effects in the heart, 
vasculature, lung, kidney and liver. RLX increases arterial compliance, reduces vascular 
resistance and increases cardiac output, with the vasodilatory properties largely mediated via 
nitric oxide. RLX inhibits pathological collagen expression from fibroblasts in response to 
pathological stimuli, without effecting basal levels of collagen, and can suppress cardiac 
arrhythmias through increased Nav1.5 protein expression, sodium current and altered Cx43 
phosphorylation and localization. To fully appreciate RLX’s pleotropic effects, it is important to 
note that different actions occur on a different time-scale. For instance, Piedras-Renteria et al 
[74, 75] showed that RLX reduces ITO within minutes after its addition to atrial muscle. 
Similarly, Han et al [73] showed that RLX acts acutely on Ca2+ currents in rabbit sinoatrial node 
pacemaker cells. In contrast, several reports indicated that RLX changed the genomics of cells 
and tissues to increase the expression of cardiac ion channel protein and to decrease the 
expression of collagen; processes that occur over a period of 24-72 hours.[13, 14, 43] Still other 
actions of RLX such as the reversal of fibrosis require approximately 2-weeks of RLX 
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treatment.[11, 13, 14] These findings point to the need to design a treatment protocol that is 
suitable to an experimental or clinical objective. 
The RELAX-AHF clinical trial tested RLX as a therapy for acute decompensated heart 
failure at a dose of 30μg/kg/day for 2-days delivered intravenously.[123] RLX was well 
tolerated, safe and significantly reduced 180-day mortality.[123] In a subsequent trial (see 
www.Novartis.com), RLX had no beneficial effects compared to standard of care perhaps due to 
an inadequate treatment protocol. Little is known regarding the dynamics of endogenous RLX in 
normal males and non-pregnant females and there is the possibility that the hormone levels are at 
picomolar or sub-picomolar levels and pulsatile in the blood stream. Future studies should 
elucidate the molecular mechanisms that stimulate RLX synthesis, the cells that secrete RLX and 
the normal range of RLX in the blood stream. With a better understanding of RLX biology and 
the development of long-lasting stable RLX mimetics, this hormone could be central to several 
new and effective therapies. 
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2.0  Hypotheses 
Based on work by Liang et al [82] suggesting that canonical Wnt signaling could regulate 
expression of the voltage gated sodium channel, Nav1.5, and its associated current, INa, we 
hypothesized that RLX would inhibit genomic expression of canonical Wnts and block Wnt 
signaling (see also sections 3.1 and 5.1). Surprisingly, we discovered that RLX activates 
canonical Wnt signaling, and therefore tested the hypothesis that canonical Wnt signaling was 
necessary for the increased expression of Nav1.5 in a rat model of aging (see also sections 3.2 
and 5.2). Finally, based on RLX’s anti-arrhythmic and anti-fibrotic properties, we hypothesized 
that RLX would be a beneficial therapy in a rat model of pulmonary arterial hypertension, to 
reduce fibrosis and suppress ventricular arrhythmias (see also sections 3.3 and 5.3).  
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3.0  Specific Aims 
Aim 1. To test the hypothesis that aging altered and relaxin reversed gene expression which 
could lead to fibrosis and action potential conduction alterations, RNA-sequencing was 
performed on young and aged rats with or without RLX treatment (see section 5.1). 
Aim 2.  Based on data from Liang et al [82], Asimaki et al [83, 124] and Chelko et al [84], 
showing Wnt signaling altered Nav1.5, Cx43 and β-catenin expression, we tested the hypothesis 
that RLX modulates Wnt signaling to mediate increased Nav1.5 expression in aged rats (see 
section 5.2).  
Aim 3.  Based on RLX’s anti-fibrotic and anti-arrhythmic actions, we tested the hypothesis that 
RLX would be a beneficial therapy to rats with pulmonary arterial hypertension (which suffer 
from ventricular arrhythmias, asystole and pulmonary and cardiac fibrosis) through improved 
action potential conduction velocity, suppression of ventricular arrhythmias and reduced 
cardiovascular and pulmonary fibrosis (see section 5.3). 
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4.0  Methods 
Animal models 
Young (9-month-old) and aged (24-month-old) male and female F-344/Brown Norway 
rats were obtained from the National Institute of Aging (Chapter 5.1 and 5.2). Rats were treated 
with vehicle (sodium acetate) or RLX (400 μg/kg/day) for 14 days via subcutaneous osmotic 
mini pumps. Left ventricular tissue was snap frozen in liquid nitrogen and stored at -80 degrees 
Celsius until use. Studies were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at 
the University of Pittsburgh. 
A total of 36 male Sprague Dawley rats (Chapter 5.3; mean weight 300 g, Charles 
Rivers) were included in the study.  A subset of animals (n=27) received the VEGFR2 antagonist 
SU5416 (Sigma). SU5416 was dissolved in CMC buffer (0.5 % sodium carboxymethyl cellulose, 
0.4 % polysorbate 80, 0.9 % sodium chloride, and 0.9 % benzyl alcohol) and was given as a 
single 20 mg/kg subcutaneous injection. The control animals (n= 9) received subcutaneous 
injection of vehicle (2ml/kg). Next, animals were implanted with osmotic mini-pumps (Alzet 
Cupertino, CA, Model 2ML4) on day zero and were replaced on day 28 to deliver: the vehicle 
(Na-acetate, n=11), 30 (n=8) or 400 µg/kg/day (n=11) of RLX for 6weeks. The rats were placed 
in a hypoxic chamber (10% O2) for 3-weeks followed by 3-weeks in a normoxic environment 
(21% O2). Blood samples were taken from each rat at the beginning (day zero) and the end of the 
experiments (day 42) and tested for levels of RLX using an ELISA assay (ELISA Kit, R&D 
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Systems, DRL200-Human Relaxin-2 Quantikine). Relaxin levels in the blood stream were below 
detectable levels for control rats at day 42. At day 42, RLX levels were 2.6±1 ng/mL and 15±12 
ng/mL, respectively for rats treated with the low or high-dose of RLX.  
 All animals received humane care in housing facilities at the University of Pittsburgh in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the 
National  
Institutes of Health (publication 85-23, revised 1985). The study protocol was approved 
by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Relaxin 
was the generous gift Dr. Mario Bigazzi and Dr. Daniele Bani and the Foundation for Research 
on Relaxin in Cardiovascular and Other Diseases.   
RNA-sequencing 
Three animals were analyzed from male groups and four animals from female groups 
(24-month-old ± RLX, 9-month-old ± RLX). A total of 1 μg of RNA was sent to the University 
of Pittsburgh Genomics Core for sequencing and library preparation. Library preparation was 
performed using the TruSEQ Stranded Total RNA Sample Preparation Kit (Illumina, San Diego, 
CA) according to manufacturer’s instructions. Following removal of ribosomal sequences, RNA 
was fragmented for 8 minutes and reverse transcription performed. Double stranded cDNA was 
subjected to 3’ adenylation and ligation of sequencing adapters. Sequencing was carried out on a 
NextSeq 500 (Illumina) for 2 x 75 bp paired end reads. Loading concentration was 1.4 pM for 
females and 1.2 pM for males. 
RNA-sequencing analysis 
Raw transcript data was imported into Biomedical Genomics Workbench 3.0.1 and 
reads were mapped to the rat reference genome. Differentially expressed genes (DEGs) used in 
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pathway analysis were determined between old and young rats with and without RLX using 
filters to select genes with Reads Per Kilobase of transcript per Million, RPKM  1, absolute fold 
change (FC) > 1.5 using total gene count and a false discovery rate (FDR)  0.05. Fisher’s exact 
test was used to test for pathway significance. Activation (z-score > 2, orange bars) or 
inhibition (z-score < 2, blue bars) of each pathway was determined by Ingenuity Pathway 
Analysis (IPA) and is a measure of experimentally determined gene expression changes 
reported in the literature. For reporting of individual genes, data are presented as FC with p-
value and FDR. DEGs filtered for pathway analysis were imported into Ingenuity Pathway 
Analysis and MetaCore to determine signaling pathways and upstream regulators affected by 
aging or RLX treatment. Aging studies were carried out by comparing RNA-seq data from 24-
month old untreated (UNT) vs. 9-month old UNT rats. RLXs effect was measured by 
comparing 24-month-old + RLX vs. 24-month-old UNT rats. The data from this publication 
have been deposited in NCBI’s Gene Expression Omnibus (GEO), and are accessible via GEO 
series number GSE106377 at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106377. 
Immunofluorescence 
Male (n = 3-4/group) and Female (n = 5/group) left ventricular tissue were thawed and 
fixed in 2% PFA at room temperature and left in 30% sucrose for 24 hours at 4 degrees Celsius. 
LV tissue sections (7 μm) were placed in 0.1% Triton 100-x for 10 minutes. Sections were 
blocked with 2% BSA for 30 minutes followed by a 90-minute incubation with primary 
antibodies, rabbit-anti-F4/80 polyclonal (Thermo Fischer, PA5-21399), mouse-anti-CD4 
monoclonal (BioRad, MCA55GA), and mouse-anti ANP monoclonal (Santa Cruz 
Biotechnology, sc515701), Guinea Pig and Rabbit anti-Nav1.5 (AGP-008, Alomone Labs, 1:200 
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in tissue and ab56240, Abcam, 1:200 in cells), rabbit anti-β-catenin (ab32572, Abcam, 1:250), 
mouse anti-Cx43 (sc-13558, Santa Cruz Biotechnology, Inc, 1:100), rabbit anti-collagen I 
(ab34710, Abcam, 1:200), mouse anti-Wnt1 (10C8, Thermo Fisher, 1:200). Sections were 
washed 3x 5minutes and incubated with secondary antibodies for 45 min and another wash. 
Finally, sections were stained for 1 minute with DAPI and coverslips mounted with gelvatol. 
Images were taken on an Olympus Fluoview inverted confocal microscope at 60x magnification. 
Image parameters were obtained for one image and kept constant throughout imaging. Images 
were analyzed using ImageJ software and only circular staining with a clear association with a 
nucleus were included in the macrophage and T-cell analysis. ANOVA was used to determine 
statistically significant differences between groups with Tukey’s post hoc analysis. Data is 
presented as mean ± SEM. P<0.05 was considered statistically significant. 
Plasma relaxin concentration: 
Circulating levels of RLX in the aged rats were determined using a pre-packaged 
Quantikine ELISA kit (R&D Systems, DRL200) according to manufacturer instructions. 
Optical Mapping: 
The optical mapping apparatus was described in detail in several reports [125,126]. 
Briefly, hearts were excised and perfused on a Langendorff apparatus with Tyrode’s solution 
containing (in mM): NaCl (130), KCl (4.5), KH2PO4 (0.6), Na2HP04 (0.6), MgSO4 (1.2), 
HEPES (10), NaHCO3 (24), Glucose (50), gassed with 95% O2 and 5% CO2, pH 7.0 at 37 oC. 
Hearts were placed in a custom-designed chamber to abate motion artifacts and blebbistatin (5-7 
μM) briefly added to the perfusate to minimize movement artifacts. Bolus injections of voltage 
(RH 237 50 μl of 1 mg/mL dimethyl sulfoxide (DMSO)) and Ca2+-indicator dye (Rhod-2/AM, 
80 μl of 1 mg/mL DMSO) were made in the air-trap above the aortic cannula. Fluorescence from 
 28 
the epicardium was collected with a camera lens, split with a 570 nm dichroic mirror and focused 
on two CMOS cameras (Sci-Media UltimaOne) capturing at the fluorescence emission at 570-
595 nm for cytosolic Ca2+ and 610-750 nm wavelengths for voltage. The hearts were paced at 
various cycle lengths (CL) and with programmed stimulation, starting with a baseline CL for 10 
beats at S1-S1=250 ms followed by a single S2 pulse delivered at decreasing S1-S2 intervals. 
Pacing protocols were used to measure CV at various stable CLs (S1-S1) and CV restitution 
kinetics was measured through the CV of the premature impulse delivered at decreasing S1-S2, 
until the premature impulse failed to capture or triggered an arrhythmia. 
Immunohistochemistry: 
Tissue sections (7 μm) were treated with 0.1 % Triton X-100 followed by block with 2% 
BSA. Primary antibody was added for 1 hour at room temperature. antibodies were used to 
measure protein expression. Secondary antibodies were applied for 1 hour at room temperature. 
Immunofluorescence imaging was performed using an Olympus Fluoview inverted confocal 
microscope or an Olympus Provis light microscope. Isolated cardiomyocytes and fibroblasts 
were stained in a similar manner after fixation with 4% paraformaldehyde. ImageJ was used for 
image analysis. 
Myocyte Isolation: 
Excised hearts were placed on a Langendorff apparatus and perfused for 4 minutes with 
Perfusion Buffer containing (in mM): NaCl (130), KCl (14.7), KH2PO4 (0.6), Na2HP04 (0.6), 
MgSO4 (1.2), HEPES (10), NaHCO3 (4.6), Taurine (30), BDM (10), Glucose (5.5), pH 7.0. 
Heart was perfused for 11-14 minutes with digestion buffer containing: 50 mL Perfusion Buffer 
with 2 mg/mL Collagenase Type II. Heart was placed in small glass beaker with 3 mL digestion 
buffer and minced into small pieces with surgical scissors. Additional mincing was conducted by 
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cutting plastic transfer pipettes at 45 degrees at largest diameter, slowing reducing pipette 
diameter size as tissue becomes solubilized. Stopping buffer (10 mL) was added containing: 45 
mL Perfusion Buffer, 5mL of 10% FBS and 12.5 μM CaCl2. Myocytes were transferred to a 50-
mL tube through a cell strainer primed with stopping buffer and allowed to pellet (~20 minutes). 
Myocytes were washed with Calcium re-introduction solutions (100 μM, 400 μM and 900 μM: 
diluted in stopping buffer) with pelleting allowed between washes. Cells were mixed with plating 
medium containing: 10% FBS, Blebbistatin (25 μM), HEPEPS (10 mM), ATP (2 mM) and 
PrimocinTM (diluted 50 mg to 500 mL MEM, Invivogen, San Diego, CA. USA). Cells were 
placed on laminin coated coverslips, in 24 well plates and incubated at 37 oC for 2 hours. Plating 
medium was replaced by culture medium containing: 0.1% BSA, Blebbistatin (25 uM), HEPES 
(10 mM), ITS (250 uL of 100x stock) and PrimocinTM. 
Picro-Sirius Red Stain: 
Left ventricular sections (7 μm) were washed in Xylene followed by washes in 100% and 
95% EtOH. Tissue was placed in Hematoxylin, followed by tap water wash and Picro-Sirius Red 
application. This was followed by washes with acidic water, 100% EtOH and Xylene. Finally, 
coverslips were mounted onto slides with Permount. Imaging was performed using an Olympus 
Provis Light Microscope at 10x magnification. Data is reported as collagen:tissue ratio. 
Fibroblast Culture: 
Primary cardiac fibroblasts isolated from the male F-344 rat model were grown to 80-
90% confluence and washed with HEPES BSS (100μL/cm2), followed by Trypsin/EDTA 
(100μL/cm2) for less than 5 minutes, and Trypsin Neutralization Solution (100μL/cm2). Solution 
was then spun down for 3 minutes at 220 x g followed by resuspension in pre-warmed growth 
media. Cells were counted and stored in Cryo-SFM media (PromoCell, C-29910) at -80 ⁰C for 
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slow freezing for 24 hours and moved to -120 ⁰C for long term storage. Frozen fibroblasts were 
thawed at 37 ⁰C until no ice remained in the vial (~2 minutes). Fibroblasts were seeded between 
5,000-10,000 cell/cm2. Media (PromoCell, C-23130) was replaced after 24 hours and every 2 
days thereafter until 90% confluency was reached. Fibroblasts were treated with RLX (25 nM), 
TGFβ (2ng/mL), Dkk (0.1 μg/mL), Wnt1 (0.1 μg/mL) and Wnt3a (0.1 μg/mL). 
RT-PCR Analysis 
RNA was isolated (RNAEasy, Qiagen) and copied to cDNA (High Capacity Reverse 
Transcription kit, Applied Biosystems) according to manufacturer protocols. A Syber-green-
based formulation (Absolute Sybr-Green, Thermo Fischer Scientific, Waltham, MA) was utilized 
for fluorescence-based kinetic real-time PCR using an Applied Biosystems model 7000 detection 
system (Applied Biosystems Inc., Foster City, CA). Expression levels of RNAs of interest were 
normalized to that of GAPDH using the ΔΔCt method, and reported relative to the mean of the 
WTV group. Primer pair sequences (forward and reverse for each target, listed 5’ to 3’) used for 
RT-PCR are as follows: 
MMP-2: gcaccaccgaggattatgac, cacccacagtggacatagca; 
MMP-9: cctctgcatgaagacgacataa, ggtcaggtttagagccacga; 
αSMA: tggctgatggagtact-tc, gatagagaagccaggatg; 
Wnt1: cctgcacctgcgactacag, ggttcatgaggaagcgtagg 
GAPDH: agctggtcatcaatgggaa, atttgatgttagcgggatc. 
Western Blot 
Protein from aged rat lysates ± RLX (n=3/group) was separated using pre-cast Mini-
PROTEAN TGX 7.5% polyacrylamide gels and transferred to a PVDF membrane. Membranes 
were then probed for mouse anti-DKK1 (1:500, Santa Cruz sc374574) and rabbit anti-α-tubulin 
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(1:1000, Abcam, ab4047). Membranes were developed using Pierce ECL Western Blotting 
Substrate (ThermoScientific, #32109) according to manufacturer instructions and developed by 
autoradiography. Quantification of the optical density of DKK1 or tubulin bands were performed 
using ImageJ software and DKK1 expression was normalized to α-tubulin. 
Right ventricular pressure and Doppler Flow Measurements  
 Right ventricular hemodynamics were assessed from simultaneously collected Doppler 
flow (DSPW, Indus Instruments, Webster, TX) and direct right and left ventricular pressure-
volume measurements (Transonic, Scisence and IOX2, EMKA). Briefly, rats were anesthetized 
using isoflurane and intubated before opening the thorax to expose the heart and lungs. The 
admittance pressurevolume catheter tip was inserted into the RV to measure RV pressure. 
Pulmonary artery Doppler flow velocities were simultaneously measured as PA pressure and RV 
pressure. All signals were stored, and post-process analysis was performed using a combination 
of commercial analysis software and custom Matlab programs (R2014a, MathWorks, MA).   
Pulmonary artery Doppler flow velocity envelopes were traced and used to calculate 
mean velocity. Stroke distance was determined from the integral of the velocity envelope and 
converted to stroke volume assuming a 2.5 mm diameter of the pulmonary artery (stroke volume 
= stroke distance x cross sectional area). Cardiac output was calculated as the product of stroke 
volume and heart rate.   
Programmed Stimulation   
Arrhythmia vulnerability was tested by pacing each heart from the LV or RV using a 
programmed stimulation protocol consisting of 10-20 S1 pulses at 250 ms cycle length (CL) 
followed by a premature S2 pulse with progressively shorter S1-S2 interval steps: from CLs of 
250 to 100ms, S1-S2 decreased in 20ms steps; from 100 to 60ms in 10ms steps and 60 to 35ms 
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in 5ms steps, until loss of capture or the initiation of an arrhythmia.  APD Restitution Kinetics 
(RK) curves were generated by plotting mean APD75 (from a minimum of 100 pixels on RV or 
LV versus S1-S2 interval in milliseconds. CV RK curves were generated by plotting the mean 
CV vs. S1-S2 interval in milliseconds. Transient ventricular arrhythmia lasted 5-15 seconds and 
self-terminated, whereas sustained ventricular arrhythmia lasted >3 minutes and could be 
terminated with a bolus injection of 1 M KCl.  
RV hypertrophy: Fulton Index and RV/Tibia ratio  
RV weights normalized to tibia length were used as indexes of RV mass. Fulton index 
(weight of RV/weight of LV + septum) was used as an index of RV hypertrophy.  
Histology (PAH rats) 
RV and LV tissues (n>4/group) were fixed in 2% PFA, equilibrated in 30% sucrose and 
flash frozen.  Frozen sections (5-μm) were stained with Mason’s Trichrome and imaged with an 
Olympus Provis AX70 microscope at 10x magnification. Four random images were taken from 
each tissue section for analysis.  Once optimal imaging parameters were determined, all 
subsequent images were obtained using the same conditions.  Analysis was performed using 
ImageJ software.  Collagen I to tissue area ratio was calculated as previously described.[23] 
Comparison of groups to control or SuHx was done using ANOVA in GraphPad Prism, and 
p<0.05 was considered statistically significant.   
The right bronchus was ligated, and the right lung was stored at -80ºC. The left lung was 
inflated and fixed with 10% buffered formalin at a height of 25 cm and immersed in formalin for 
at least 72 h before being embedded. Serial tissue sections (5-µm) from paraffin-embedded lungs 
were deparaffinized and stained with hematoxylin and eosin (H&E), Mason’s trichrome, and 
Verhoeff’s Van Gieson (VVG) for assessment of occlusive and plexiform lesions and 
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perivascular fibrosis.  Lungs from control, SuHx, low-dose (RLX LD), and high dose (RLX HD) 
(n=4 per group) rats were embedded in paraffin, sectioned (5-μm) and stained with Mason’s 
Trichrome. Collagen Images were taken with an Olympus Provis AX70 microscope at 10x 
magnification so that the entire surface area of each tissue was imaged. Fibrosis was analyzed as 
the collagen-to-tissue ratio using ImageJ software. Airspaces in the tissue were excluded in the 
analysis. The statistical significance of average collagen difference between groups was 
evaluated using ANOVA in GraphPad Prism. P<0.05 was considered statistically significant. 
Pulmonary media vascular remodeling was assessed by staining pulmonary arterial wall smooth 
muscle cells with a mouse monoclonal and anti-smooth muscle-alpha actin antibody at a dilution 
of 1/100 (Laboratory Vision, Fremont, CA). The Aperio ScanScope XT system (Aperio Inc, 
Vista, CA, USA) was used to scan entire glass slides at 20x or 40x magnification and Aperio 
ImageScope software was used to analyze digital slides.   On average, between 70-110 small size 
pulmonary arteries (<50 μM) per animal were analyzed for pulmonary vascular remodeling 
(neomuscularization), incidence of occlusive vascular lesion, and presence of plexiform lesions 
(PLX) and expressed as number of PLX per slide or normalized by number of examined small 
size arteries.   
Statistical Analysis: 
Comparisons between two groups were done using an unpaired, 2-tailed t-test, or the 
Mann-Whitney U test. Comparisons of three or more groups were done using ANOVA or 
Kruskal-Wallis tests. Nuclear β-catenin was compared using Chi-squared. All data is presented 
as mean ± SEM, unless otherwise noted. Statistical comparisons were performed using Graphpad 
Prism software. A value of P<0.05 was considered to be statistically significant. 
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5.0  Results 
In order to more fully understand the long-term beneficial effects of RLX in HF, AF and 
fibrosis, as described in Chapter 1, we investigated the underlying effects of RLX on gene 
expression using RNA-sequencing in our aged rat model of disease.  
Aging is a major risk factor for atrial fibrillation (AF) [127] and heart failure (HF), [128] 
which may reach pandemic proportions due to an increasingly aging population, estimated to 
reach 70 million people over the age of 65 in the United States by 2030.[129] HF is defined as 
the inability of the heart muscle to pump enough blood to meet the energy demands of the body 
[13], and aging is associated with multiple maladaptive vascular and cardiac structural, electrical 
and functional changes that increase the susceptibly to HF, AF and other cardiovascular diseases 
(CDs). [13, 129] Structural remodeling in aging includes: increases in vascular stiffness, left 
ventricular (LV) and aortic wall thickness [129], fibrosis [131] and myocyte hypertrophy that 
promote diastolic dysfunction, coronary heart disease, [129] AF [132] and HF. [131] In sum, 
age-related maladaptive responses lower the threshold for CD development. [131] Recent 
evidence posits that aging brings-on the gradual development of a chronic, low-grade 
inflammation, termed “inflammaging” which is possibly the greatest risk factor for many age-
related diseases. [133] Chronic inflammation can result from failed resolution of an injury by the 
body or stimuli resulting in asymptomatic responses.[134] Inflammation has been linked to 
multiple CDs including myocardial infarction, resulting in increased leukocyte infiltration that 
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leads to pathological left ventricular (LV) remodeling.[135] In addition, complement cascade 
activity can be activated in the presence of pathogens or tissue injury and has been linked to 
higher hospitalizations and mortality in ischemia/reperfusion studies, [134, 136] and to 
inflammation associated with insulin resistance and type II diabetes. [137] Interleukin (IL)-1 and 
IL-6 have been linked to cardiac hypertrophy, reduced contractility, increased arrhythmia 
susceptibility, increased C-reactive protein, coronary artery disease [138] and raise stroke risk, 
while tumor necrosis factor alpha (TNFα) is associated with LV dilatation and dysfunction and 
HF progression. [139-141] In addition to inflammatory markers of disease, multiple markers are 
used clinically to determine HF progression and prognosis. Brain natriuretic peptide (BNP, gene: 
NPPB) is a marker of HF, is indicative of hemodynamic wall stress and is a risk factor for AF 
and HF. [140, 142, 143] Like BNP, atrial natriuretic peptide (ANP, gene: NPPA) is a marker of 
congestive HF [144] and growth differentiation factor (GDF)-15 is implicated in HF and 
inflammatory and oxidative stress. [143, 145] Clinical trials that suppressed the inflammatory-
related cytokine, TNFα, have yielded disappointing results in chronic HF patients. TNFα 
chelation had no effect on primary endpoints of hospitalization and death, leading investigators 
to hypothesize a large degree of redundancy in the immune response related to HF, so that 
targeting a single cytokine may prove to be ineffective. [136] Studies in patients with rheumatoid 
arthritis using tocilizumab to block IL-6 signaling through the IL-6 receptor have shown 
beneficial effects, though resulted in side-effects including pro-atherogenic dyslipidemia and 
increased low density lipoprotein (LDL), [138] which is associated with increased risk of 
coronary artery disease. [146] 
Although age is a major risk factor for inflammation, AF and HF, [133, 147, 148] with 
few exceptions [148–150] there is a noticeable paucity of genetic studies on how global gene 
 36 
expression is altered in normal, ‘healthy’ cardiac aging. Many were done in mice despite the 
challenge of comparing age-related gene expression patterns in mice and man. Yet, differences 
in mice may be due to a non-uniform rate of aging in mice.[149] since other studies identified 
aging gene expression signatures that are conserved in mice, rats and humans, namely, 
inflammation and the immune response. [148]. This suggests that genomic studies of 
inflammation in rodents may be relevant to the development of therapies for disorders related to 
age and inflammation. Furthermore, the challenges of using mouse models of aging are largely 
dispelled through the use of the F-344 Brown/Norway rat model from the National Institute of 
Aging, which has been developed and used extensively to study the effects of aging due to its 
homogeneous and linear rate of aging, increased cardiac collagen production and increased 
susceptibility to atrial fibrillation and systolic and diastolic dysfunction; all hallmarks of human 
aging. [132, 151, 152] 
Relaxin (RLX), a hormone of pregnancy, has shown significant cardiovascular benefits 
including a significant reduction in AF susceptibility in aged [13] and hypertensive [14] rats, 
primarily through a reversal of fibrosis and an increase in voltage gated sodium channels, 
Nav1.5, and its current, INa. In phase II clinical trials, RLX reduced 180-day cardiovascular and 
all-cause mortality in acute decompensated HF patients after 48-hour RLX infusion; [110, 112] 
however, recent Phase III clinical trials failed to meet the primary endpoint of reduced mortality 
in HF patients (https://www.novartis.com/ news release, March 2017), though details are yet to 
be published. In spite of these results, RLX has been shown to be a potent anti-fibrotic through 
regulation of fibroblast activation, collagen secretion and reductions in pro-fibrotic 
transcripts,[13, 43] a suppressor of AF through a combination of structural and electrical cardiac 
remodeling,[13, 14] and to increase vascular compliance and reduce systemic vascular 
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resistance.[24, 43] In addition, we report here RLX’s anti-inflammatory actions, suggesting that 
RLX acts on multiple signaling pathways and may be a therapy for various diseases associated 
with these pathological conditions. Despite growing evidence of RLX’s beneficial effects, [4, 11, 
13, 14, 153] the mechanisms underlying these effects remain unclear. In RELAX-AHF trials, 
RLX serum concentrations rose rapidly, levelled off after 4 hours of infusion, and decreased 
quickly post-infusion.[108] The short lifespan of RLX (~2hrs) suggests that the long-term 
benefits of RLX stem from long-lasting genomic effects rather than an improvement of 
hemodynamics at the time of infusion.[110] Here, we test the hypothesis that RLX acts at the 
genomic level to modify HF and AF related genes and signaling pathways that are activated or 
inhibited in ‘healthy/normal’ aging. We show that aging significantly increases gene 
transcription of multiple pro-inflammatory and HF related genes and signaling pathways. 
Significantly, we show that RLX reverses the effects of aging in both genders through genetic 
regulation of these pathways and that aging increases macrophage accumulation in females, but 
not male left ventricles, which is reversed by RLX treatment. These data provide evidence in 
support of RLX as a therapy for a plethora of inflammatory diseases through its regulation of 
multiple cytokines and signaling pathways. 
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5.1 Relaxin Reverses Cardiac Inflammation 
 
 
Effects of aging and relaxin on biomarkers of AF and HF 
In the clinical setting, several markers have been associated with the severity and/or 
mortality of AF and HF patients. In a proteomics study of AF, Lind et al [140] reported an 
association of multiple proteins with AF using two cohorts. The primary cohort included both 
genders and a validation cohort included only males. It is interesting to note that they reported 
thirteen AF associated proteins in the mixed gender cohort, but merely 5 in the male only cohort, 
suggesting marked gender differences. Table 2 lists age and RLX-dependent transcription 
changes of multiple markers thought to be involved in AF and HF development. [139-143, 154-
157] RNA-sequencing (RNA-seq) analysis showed that aging and aging plus RLX-treatment 
altered with high significance (FDR<0.05) more than 7 genes associated with HF and AF in the 
clinical setting. In Table 2, these genes are highlighted in bold and dark shading and genes 
exhibiting highly significant changes have double-check marks. In females, aging or RLX 
altered atrial natriuretic peptide (NPPA), interferon gamma (INFG) and the LDL receptor 
(LDLR). In males, aging or RLX altered IL-1β, IL-6, NPPB, and GDF-15. In addition, several 
genes exhibited > 1.5 absolute fold changes with p<0.05, but do not reach the more stringent 
criterion of FDR<0.05 and are labeled with a single check mark. RLX significantly reversed 
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multiple transcripts associated with HF and AF and therefore appears to not only stop the 
progression but to reverses the pathological expression of many cytokines. 
Atrial natriuretic peptide (ANP), the most differentially expressed gene in female rats, was 
selected for further protein expression analysis to confirm that the effects of RLX on gene 
expression had functional consequences. In female rats, 9-month-old controls (Fig 2A) exhibited 
significantly less ANP than in aged ventricles (Fig 2B). RLX treatment (Fig 2C) significantly 
reversed aging’s effect on ANP expression. In male rats, there was no significant change in ANP 
expression in the aged versus the young controls (Fig 2E, 2F and 2H), though there was a 
reduction in ANP with RLX treatment (Fig 2G and 2H), that did not reach statistical 
significance. These data match closely the gene expression data in Table 2 (NPPA) for ANP 
expression. 
Upstream analysis (Table 3) searches for differentially expressed genes (DEGs) to 
predict activation or inhibition of transcription regulators and to determine which molecules can 
explain gene expression alterations observed in the data sets. Observed DEGs are compared to a 
database of known interactions with transcriptional regulators kept by Ingenuity, with transcripts 
grouped together under common regulators. 
 The quantity of genes controlled by a given transcriptional regulator and the agreement 
of direction (+/-) of fold change of each DEG to that reported in the literature, leads to a 
prediction of activation or inhibition of those transcriptional regulators. 
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Table 2. RNA-Sequencing Analysis of Cardiovascular Disease Related Genes in Aging. FDR: False Discovery Rate. Multiple test correction 
technique used in RNA-sequencing data analysis. Underscores indicated gene isoform. Bold: at least one group shows FDR < 0.05. ns: not 
significant. Yellow,✓✓: FDR<0.05. Blue,✓: Fold Change > 1.5, p<0.05. 
 Female 
Fold Change (p-value, FDR) 
Male 
Fold Change (p-value, FDR) 
Gene Aging RLX Aging RLX 
IL-1β -1.24 (ns) 1.48 (ns) -1.69 (0.02, ns) -3.54 (<0.0001, <0.01) ✓✓ 
IL-6 1.82 (0.03, ns) ✓ -1.81 (0.04, ns) ✓ 1.15 (ns) -4.35 (<0.0001, 0.01) ✓✓ 
IL-6RA 1.09 (ns) -1.20 (ns) -1.10 (ns) 1.21 (ns) 
CRP Undetected Undetected Undetected Undetected 
TNFα -1.63 (ns) ✓ 2.67 (<0.01, ns) ✓ -1.87 (<0.01, ns) ✓ -1.82 (0.03, ns) ✓ 
NPPB 1.00 (ns) 1.28 (ns) 1.43 (0.04, ns) ✓ -1.84 (<0.0001, 0.01) ✓✓ 
NPPA 10.48 (<0.0001, <0.0001) ✓✓ -2.95 (0.01, ns) ✓ 1.37 (ns) -1.36 (ns) 
GDF-15 -1.45 (0.07, ns) 1.37 (ns) 1.40 (ns) -3.58 (<0.0001, 0.03) ✓✓ 
SPP1 2.64 (<0.01, ns) ✓ -2.24 (<0.01, ns) ✓ -1.10 (ns) -3.42 (<0.01, ns) ✓ 
CST3 1.35 (0.01, ns) -1.47 (0.04, ns) 1.02 (ns) -1.46 (<0.01, ns) 
IFNG 6.10 (<0.0001, <0.01) ✓✓ -3.25 (<0.01, ns) ✓ -2.48 (0.03, ns) ✓ 1.09 (ns) 
FGF-23 1.41 (ns) -1.14 (ns) -4.44 (<0.01, ns) ✓ 1.28 (ns) 
FABP4 1.25 (ns) -1.09 (ns) 1.81 (<0.01, ns) ✓ -1.03 (ns) 
CSTB 1.28 (0.02, ns) -1.18 (ns) 1.39 (ns) -1.47 (ns) 
IL-1RA 1.78 (<0.01, ns) ✓ -1.32 (ns) 2.11 (0.04, ns) ✓ -2.12 (0.03, ns) ✓ 
TNF-R1 -1.34 (0.04, ns) 1.14 (ns) -1.16 (ns) -1.16 (ns) 
TNF-R2 1.05 (ns) -1.17 (ns) -1.19 (ns) 1.18 (ns) 
Plaur_1 1.2 (ns) -1.6 (0.02, ns) ✓ -1.21 (ns) -1.39 (ns) 
Plaur_2 1.77 (ns) -1.76 (ns) 1.85 (ns) -5.56 (<0.01, ns) ✓ 
Plaur_3 2.65 (0.01, ns) ✓ -3.55 (<0.01, ns) ✓ -1.2 (ns) -5.29 (0.01, ns) ✓ 
CSF-1 1.4 (<0.01, ns) -1.18 (ns) 1.23 (ns) 1.21 (ns) 
AM 1.42 (0.01, ns) -1.25 (ns) 1.06 (ns) -1.14 (ns) 
TNNT2_1 -1.05 (ns) 1.21 (ns) 1.3 (ns) -1.53 (<0.01, ns) ✓ 
TNNT2_2 -1.13 (ns) 1.2 (ns) 1.26 (ns) -1.26 (ns) 
LDLR -1.91 (<0.01, 0.05) ✓✓ 1.56 (0.01, ns) ✓ -2.52 (<0.01, ns) ✓ 1.32 (ns) 
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Fig 2. Protein Expression of ANP in Female and Male Hearts. A-D. Female. Female aging (B) resulted in upregulation of ANP expression 
compared to young controls (A) and was reversed by RLX (C). D. Quantification of ANP expression in female LV. E-H. Male. In male rats, 
aging (F) did not increase ANP expression compared to young controls (E), though there was a reduction in ANP with RLX treatment (G) though 
this did not reach significance compared to young or aged males. H. Quantification of ANP expression in male LV. Red: ANP. : p<0.0001. Scale 
bar: 50μm. 
 
 
Table 3. Upstream Analysis of RNA-sequencing Gene Expression Data 
 Female  Male 
Upstream regulator Aging  RLX Aging RLX 
Hydrogen Peroxide   Inhibited  Inhibited 
NFkB (complex) Activated  Inhibited  Inhibited 
TLR4 Activated    Inhibited 
IFNG Activated  Inhibited  Inhibited 
IL6 Activated  Inhibited  Inhibited 
LPS Activated  Inhibited  Inhibited 
Sirolimus Inhibited    Activated 
TGFβ1 Activated  Inhibited  Inhibited 
SMAD7 Inhibited  Activated Activated  
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Table 4. Chemokine and Chemokine Receptor Transcripts. FDR: False Discovery Rate. Multiple test correction technique used in RNA-
sequencing data analysis. Bold: at least one group shows FDR < 0.05. NS: not significant. Yellow,✓✓: FDR<0.05. Blue,✓: p<0.05. 
 Female 
Fold change (p-value, FDR) 
Male 
Fold change (p-value, FDR) 
Gene Aging RLX Aging RLX 
CCL1 -1.02 (ns) 1.46 (ns) -3.64 (<0.0001, 0.03) ✓✓ -1.21 (ns) 
CCL2 1.23 (ns) 1.23 (ns) 1.43 (ns) -3.26 (<0.0001, 0.04) ✓✓ 
CCL3 1.23 (ns) -2.62 (<0.01, ns) ✓ -1.15 (ns) 1.89 (0.02, ns) ✓ 
CCL5 1.79 (<0.0001, <0.001) ✓✓ -1.54 (<0.01, ns) -1.49 (<0.05, ns) 1.24 (ns) 
CCL6 1.61 (<0.0001, <0.05) ✓✓ -1.27 (0.02, ns) -1.56 (0.05, ns) 1.11 (ns) 
CCL19 2.35 (<0.001, 0.01) ✓✓ -1.87 (<0.01, ns) ✓ -1.34 (ns) -2.77 (<0.01, ns) ✓ 
CCL20 1.67 (ns) -1.35 (ns) 3.07 (<0.01, ns) ✓ -1.37 (ns) 
CCL21 -1.02 (ns) -1.48 (<0.01, ns) -2.55 (<0.0001, 0.01) ✓✓ -1.26 (ns) 
CXCL9 1.55 (<0.01, 0.02) ✓✓ -1.67 (<0.01, 0.03) ✓✓ -1.10 (ns) -1.09 (ns) 
CXCL13 2.24 (<0.0001, <0.0001) ✓✓ -1.52 (<0.01, ns) -1.07 (ns) 1.29 (ns) 
CXCL16 1.60 (<0.0001, <0.001) ✓✓ -1.27 (0.03, ns) 1.22 (ns) -1.14 (ns) 
CCR1 1.90 (<0.01, ns) ✓ 1.00 (ns) -2.01 (<0.01, ns) ✓ 1.13 (ns) 
CCR5 1.30 (ns) -1.17 (ns) -1.34 (ns) 1.18 (ns) 
 
Consistent with the effects of aging shown in Table 2, NFkB signaling, a crucial pathway 
regulating many inflammatory genes, is upregulated in female aging and inhibited by RLX in 
both female and male rats. In female rats, IFNγ, IL-6, lipopolysaccharide (LPS) and 
transforming growth factor (TGF) β1 are activated in aging and inhibited by RLX. Interestingly, 
SMAD7, an inhibitor of TGFβ1 and fibrosis, is inhibited with aging and activated by RLX; 
consistent with the anti-fibrosis properties of RLX. In aged male rats, upstream analysis failed to 
detect an activation of the genes that were activated in aged female ventricles, yet RLX still 
inhibited many of them in aged male ventricles. Note that RLX inhibited several upstream 
regulators: hydrogen peroxide, NFkB, TLR4, IFNG, IL-6 and LPS in males and females (Table 
3). 
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Besides classic inflammatory gene expression that change in HF, and aging ± RLX, RLX 
altered chemo-attractant genes involved in recruiting inflammatory and immune cells to sites of 
injury (Table 4). 
Signaling pathway analysis 
To identify signaling pathways that are affected by aging and RLX treatment, 
differentially expressed genes (DEGs) were filtered as transcripts whose absolute expression was 
altered by at least 1.5-fold, had expression values with RPKM (reads per kilobase of transcript 
per million)  1, and had a false discovery rate (FDR) < 0.05 (Fig 3). 
Female rats 
Application of Ingenuity Pathway Analysis (IPA) software to DEGs showed that female 
rats exhibit significant activation of inflammatory and immune signaling pathways with aging 
(Fig. 4A) which are reversed by RLX treatment (Fig 4B). These pathways include: 1) Calcium- 
induced T lymphocyte apoptosis pathway, which acts to counter excessive inflammatory 
response [158, 159], though may be harmful in some cases [160], 2) PKCθ signaling in T 
Lymphocytes, involved in T-cell activation and NF-κB signaling [161, 162], 3) iCOS-iCOSL 
signaling in T-helper cells, resulting in activation and migration of lymphocytes and secretion of 
both antiand pro-inflammatory cytokines [163], 4) NFAT regulation of the immune response, 
involved in cytokine production in leukocytes [164], 5) TH1 signaling, resulting in pro-
inflammatory response, compared to the anti-inflammatory TH2 signaling [165] and 6) dendritic 
cell maturation, which acts as a link between innate and adaptive immunity [164]. 
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Fig 3. Volcano Plots of Differentially Expressed Genes in Aging ± RLX treatment. A. Female aging resulted in an overall upregulation of 
transcripts, with fewer transcripts being downregulated. B. RLX treatment in females caused a marked suppression of most transcripts with few 
being upregulated. C. Transcript expression changes in males were muted compared to females during aging, with an even number of transcripts 
being up and downregulated. D. RLX treatment in males reflects that seen in females, with a substantial proportion of transcript alterations being 
suppressed compared to upregulated. Blue dots represent individual transcripts. 
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Aging increased and RLX decreased expression of a common set of genes, namely those 
associated with the major histocompatibility complex (MHC) which is involved in immune 
system signaling (Table 5). This was supported by MetaCore (Thomson Reuters) analysis that 
showed activation of antigen presentation by MHC class I & II in aging and inhibition with RLX 
treatment (data not shown). Analysis of DEGs by IPA to predict which cellular functions would 
be altered in aging or by RLX, showed that aged female rats exhibit increased gene expression 
involved in migration 
 
Fig 4. Pathway Analysis: Female. (a) Pathway analysis of female rats suggest that multiple inflammatory signaling pathways are activated 
(orange) in aging and (b) RLX treatment inhibited (blue) many of these signaling pathways. Due to the substantial number of pathways altered in 
female aging (93 pathways) and RLX treatment (58 pathways), only those pathways whose activation or inhibition was predicted by IPA (orange 
or blue colors, respectively) are shown. 
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Table 5. Common genes altered by relaxin: Female. Right column indicates which genes are common between aging and RLX groups which 
RLX reverses compared to the aging group. Arrows indicated direction of change by RLX. FCGR3A/B: Encodes receptor for Fc portion of 
immunoglobin G. HLA: human leukocyte antigen; gene complex which forms the major histocompatibility complex. LOC: indicates genes with 
uncertain functions. 
Signaling pathway Aging RLX RLXs Effect 
Role of NFAT in Regulation of the 
Immune 
Response 
Activates Inhibits FCGR3A/FCGR3B(#), HLA-DQA1(#), HLA-DRA(#), HLA-DRB5(#), 
LOC1009009593/RT 
(#) 
Dendritic Cell Maturation Activates Inhibits 
Calcium-induced T Lymphocyte 
Apoptosis 
Activates Inhibits HLA-DQA1(#), HLA-DRA(#), HLA-DRB5(#), LOC1009009593/RT(#) 
iCOS-iCOSL Signaling in T Helper Cells Activates Inhibits 
TH1 Pathway Activates Inhibits 
PKCθ Signaling in T Lymphocytes Activates Inhibits 
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Fig 5. Cellular Function Prediction from Differentially Expressed Female Genes. IPA shows that aging leads to extensive alterations of gene 
expression resulting in leukocyte activation (panel a) and antigen presentation (panel b). RLX significantly reduced the expression of multiple 
genes associated with immune activation (panel c) and antigen presentation (panel d); that is, RLX largely reversed the effect of aging on the 
immune cell response. Orange centers denote activated function. Blue centers denote inhibited function. Green genes indicate reduced expression. 
Red genes indicated increases in expression. Orange, Blue and Yellow lines: the altered genes lead to activation, inhibition of function or is 
acting in a way opposite to the current literature, respectively. Brown lines: the function of the gene is unclear in the literature. 
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and activation of leukocytes and increased antigen presentation (Fig 5A and 5B), and these 
functions are significantly reversed by RLX (Fig 5C and 5D), supporting RLXs role in MHC 
regulation.  
In addition to the signaling pathways that are reversed by RLX based on IPA, MetaCore 
analysis also showed that the classical complement cascade is significantly activated in aging 
(Fig 6A) and reversed by RLX treatment (Fig 6B) in female rats. 
Male rats 
IPA pathway analysis of male rats (Fig 7A and 7B) show a significant decrease in 
dendritic cell maturation with age (Fig 7A) and inhibition of EIF2 and IL-6 signaling with RLX 
treatment (Fig 7B). These data, again, support the notion that there are major differences in the 
regulation of gene expression in male and female rats with aging and RLX treatment. MetaCore 
analysis in male rats suggest that multiple pathways are inhibited by RLX: IL-1, CCR1, CCL2, 
HMGB1/RAGE and LPS signaling, though these are not necessarily activated by aging (not 
shown). IPA analysis in male rats, did not show an activation of immune cell recruitment in 
aging, though RLX significantly repressed immune cell activity, recruitment and accumulation 
(Fig 7C). 
These data and Tables 2–4 indicate that gender plays a vital role in terms of which genes 
are altered in aging and disease, and that treatments can affect males and females in different 
ways. 
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Fig 6. Complement Cascade Activity with Aging and Relaxin: Female. The classical complement cascade can result in an opsonization, or 
marking of cells for phagocytosis, and lysis of bacteria. It can also result in an augmented inflammatory response. A. Effect of aging on 
complement component activation. B. Effect of RLX on reversal of complement activity. Red boxes indicate significant alterations of specific 
complement components. Red and blue thermometer markers next to specific components indicate increased and decreased component 
expression, respectively. For key describing complement components, see https://portal.genego.com/help/MC_legend.pdf. 
 
Macrophage accumulation 
Based on higher IFNγ, IL-6, MHC gene expression, increased complement activation, 
and prediction of increased inflammatory/immunce cell activity by IPA in aging female but not 
male rats, we first investigated the effects of aging on macrophage and T-cell recruitment in 
female ventricular tissue by immunofluorescence (Fig 8A–8C). Tissue macrophage infiltration 
measured with the marker F4/80 [166], increased significantly in aging (Fig 8B) compared to the 
young controls (Fig 8A) and was dramatically decreased with RLX treatment (Fig 8C). Next, we 
tested the male LV for macrophage accumulation (Fig 8D–8F). Male rats had significantly less 
macrophages that did the corresponding female rats in each group. Moreover, male aging (Fig 
8E) did not significantly increase macrophage accumulation compared to the young male rats 
(Fig 8D), and RLX did not cause a significant change compared to young or aged male controls 
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(Fig 8F). Although RLX slightly increased and decreased T-cell accumulation in females and 
males, respectively, the significance is unclear because T-cells were sparse (<6/ high power 
field) in all groups (data not shown). 
Our data show that aging promotes an inflammatory response in females, but not males, 
and RLX reverses these effects in females, and suppresses many inflammatory genes in males.  
One may reasonably conclude that RLX is acting at a genomic level to suppress 
inflammatory and immune responses in male and female rat heats. Others studies have 
bemoaned that only 10% of immunology studies consider sex as an important variable [167]; and 
the current findings re-enforce this concern by showing that females and males exhibit 
drastically different gene expression patterns and signaling pathway regulation, not only in 
aging, but also by relaxin therapy. 
Reductions in IL-6 have been associated with beneficial effects in rheumatoid arthritis, though 
with increased LDL in the plasma.[138] Here, we showed that aging increased IL-6 transcription 
in females, while also significantly lowering the LDL receptor necessary to reduce LDL 
concentration in the plasma. However, RLX reduced IL-6 and increased LDLR, suggesting more 
LDL receptors and a greater efficacy at removing excess LDL cholesterol from the plasma. 
These results suggest RLX may prove to be a beneficial therapy for patients suffering from 
rheumatoid arthritis or coronary artery disease. In addition, IL-6 has been associated with type II 
diabetes development, and as such, RLX may prove to be a beneficial therapy in diabetes 
management [168]. 
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Fig 7. Pathway Analysis: Male. Male rats had negligible pathway alterations (a) with aging or (b) RLX treatment. Blue bars indicate pathway 
inhibition. IPA in males (c) showed that quantity, recruitment and accumulation of various immune cells were inhibited (green) by RLX. In 
males, aging and RLX treatment altered 24 and 46 pathways, respectively; hence only pathways whose activation or inhibition was predicted by 
IPA (orange or blue colors, respectively) are shown here. 
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The classical complement cascades converge on C3 components, which are necessary for 
C5 convertase formation and lead to inflammation (the anaphylatoxins C3a, C4a and C5a 
components) or bacteria lysis (C5b) [134]. Our data (Fig 6) shows that the C3a and C4a 
complement components are indeed two pieces, upregulated by aging and reversed by RLX. The 
anaphylatoxins can also increase activation of macrophages, resulting in increased release of 
inflammatory cytokines and stimulate the release of proteolytic enzymes which contribute to 
ongoing tissue damage and increase endothelial surface thrombogenicity. Moreover, clinical 
trials have shown that inhibition of C3 convertase attenuates both leukocyte attraction and 
mortality in cardiopulmonary bypass patients [134]. Taken together, our data suggest that relaxin 
could be a potent therapy to regulate aberrant complement activity. 
 
 
Fig 8. Effect of Aging and Relaxin on Macrophage Accumulation in the Heart. A-C. Female. Aged female left ventricles had significant 
macrophage accumulation (B. 21.47±0.86 macrophages/hpf) compared to young controls (A. 15.57±0.96) and RLX reversed this aged-dependent 
macrophage accumulation (C. 11.72±1.26). D-F. Male. Male left ventricles showed no change in macrophage accumulation in aging (E. 
2.13±0.51) or with RLX treatment (4.88±0.84) compared to young (0.65±0.27) male rats, and had less macrophages than females in each group. 
G. Quantification of macrophage accumulation. Blue: DAPI; Green: F4/80 macrophage marker; HPF: high power field. Data is reported as mean 
± SEM. N.S.: Not significant. 60x magnification. Scale bar: 50 μm. 
 
Hofmann and Frantz [136] suggested that targeting specific cytokines in pre-clinical 
studies and clinical trials have failed to produce beneficial results due to the redundant nature of 
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the immune system. Our study shows that RLX significantly alters multiple cytokines and 
signaling pathways in both genders, which could lead to improved suppression of inflammatory 
related pathophysiology that rely on these redundant immune effects. 
Franceschi and Campisi [154] report that there are at least eight possible mechanisms for 
“inflammaging”: 1) persistent leukocyte production of reactive molecules, 2) cytokine 
production from damaged non-immune cells, 3) alterations in anabolic signaling, (e.g. TNFα and 
IL6 signaling) altering insulin production, 4) “self-debris” from cell injury that accumulates over 
time, activating the inflammatory response, 5) reduced ability of the aged body to sequester 
infiltrated bacteria or viruses, 6) cellular senescence, 7) release of cytokines from damaged 
mitochondria and 8) dysregulation of the complement system. Our data supports reasons 1, 3 and 
7 in that aging increases cytokine transcript production and RLX reduces cytokine transcript 
expression and accumulation of macrophages in LV tissue in females. Needless-to say, further 
studies are needed on all possible mechanisms. Inflammation has been implicated in many 
aspects of cardiovascular disease including LV remodeling [169], hypertrophy [141], stroke 
[140], HF [139], and AF [170]. The suppression of inflammatory responses by RLX warrants 
further investigation considering its possible beneficial actions towards a therapy for such 
inflammatory related diseases as AF, diabetes, obesity and HF. 
A limitation of this study is the lack of a general consensus for quantification and 
analysis of RNA-seq data [171]. The cut-off for filtering by RPKM is arbitrary and varies greatly 
in the literature, from 0.1 [172] to greater than 5 [173]. To determine which RPKM value to use 
for gene filtering, we obtained a freely available RNA-seq dataset analyzed using TopHat 
software [174], and compared results using our current analysis software. An RPKM  1 showed 
good agreement among the results between the two software packages. Another limitation is that 
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RNA-seq was performed only on LV tissue, and it is unknown if atria or RV behave similarly. 
Finally, the experiments cannot discriminate whether RLX is removing the inflammatory 
stimulus resulting in downregulation of inflammatory markers, or is regulating transcription of 
the inflammatory markers themselves. The long-term effects following a short-term 
administration of RLX in clinical trials suggests a direct effect on transcription, and the broad 
reduction in multiple genes suggests a common nexus of action. Evidence suggests that multiple 
proinflammatory cytokines are controlled at the transcriptional level through histone 
modifications or phosphorylation.[175] Our lab showed that RLX can regulate phosphorylation 
of proteins [14], hence future studies should look into RLX’s ability to regulate histone 
modification and phosphorylation of genes. 
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5.2 Relaxin Acts Through Wnt Signaling 
 
 
As discussed above, aging is associated with structural and functional changes of the 
cardiovascular system and is a major risk factor for a number of pathologies, including atrial 
fibrillation (AF) and heart failure (HF).[8,129,176] The prevalence of age-associated 
cardiovascular disease (CD) is expected to increase steadily, with estimates reaching 70 million 
people in the United States by 2030.[129] Structural and electrical remodeling during aging 
includes excess fibrosis, cellular hypertrophy and vascular stiffening leading to hypertension, 
reduced myocyte contractility, diastolic and/or systolic dysfunction and HF.[129,176,177] Age-
dependent electrical remodeling involves ion channel and gap junction dysregulation which 
result in increased arrhythmia susceptibility.[13,14,177,178] We previously showed that the 
hormone relaxin (RLX) suppressed AF in aged (24-months old) rats by increasing conduction 
velocity (CV) of atrial action potentials.[13] These effects were linked to increased expression of 
the voltage-gated sodium channel Nav1.5, increased current (INa), and a marked decrease in 
fibrosis.[13] However, the mechanisms whereby RLX acts to increase Nav1.5 and reduce 
fibrosis are largely unknown, though studies indicate that RLX suppresses TGFβ and matrix 
metalloproteases in fibrosis regulation.[13,14, 43] We reported that RLX-treatment of young (9-
months) and aged (24-months) rat (F-344 strain) ventricles resulted in a reversal of inflammatory 
and immune responses and an overall rejuvenation of cardiac properties.[8] 
Canonical Wnt signaling is a master controller in cardiac embryogenesis and 
development, but it is thought to be quiescent after birth. [82,178] In the absence of Wnt 
 56 
signaling, β-catenin is phosphorylated, marked for ubiquitination and removed by the 
proteasome. During canonical Wnt-signaling, Wnt binding to Frizzled and the co-receptors, 
LRP5/6, results in the dissociation of the β-catenin destruction complex causing the 
accumulation of β-catenin, which enters the nucleus to regulate the activity of the TCF/LEF 
family of transcription factors. Exogenous Wnt3a is routinely added to stimulate the 
differentiation of human induced pluripotent or embryonic stem cells into cardiac myocytes and 
conversely, blockade of Wnt-signaling with Dickkopf-1 (Dkk1) inhibits cardiac 
differentiation.[179] Interestingly, late antagonism of endogenous Wnts enhances cardiogenesis, 
indicating a biphasic role in human cardiac differentiation.[180,181] Besides the regulation of 
the contractile apparatus, Wnt-signaling regulates the expression of the voltage-gated Na+ 
channel Nav1.5 in neonate rat ventricular cardiomyocytes (NRVM) [82] and HL-1 cells.[182] 
Puzzlingly, Wnt3a suppressed Nav1.5 expression in NRVM,[82] whereas activation of canonical 
Wnt signaling by other means increased Nav1.5 and Connexin-43 (Cx43), and reduced 
ventricular ectopic beats in NRVM, 3-week and 6-month old mouse models of arrhythmogenic 
cardiomyopathy.[81,84,183] 
Here, we tested the hypothesis that the effects of RLX on Nav1.5 and fibrosis are 
mediated by canonical Wnt signaling. While RLX and Wnt signaling have been investigated in 
models of cancer [184-186], there is no work on the interactions of the RLX and Wnt pathways 
in adult heart and ‘healthy’ aging as a precursor of cardiac diseases. We focused on hearts from 
9-month (adult) and 24-month-old (aged) Fischer 344/Brown Norway F1 (F-344) male rats 
obtained from the National Institute of Aging. F-344 rats have been extensively studied and 
characterized as a model of aging because of their linear aging, and because, like humans, they 
exhibit an age-dependent excess of cardiac fibrosis and susceptibility to atrial 
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fibrillation.[13,132] Rats were treated with RLX (400 μg/kg/day) or vehicle (sodium acetate) via 
subcutaneous osmotic mini-pumps for 14 days, resulting in an increase in the circulating plasma 
concentration of RLX from 0.017±0.027 ng/mL to 23.76±10.60 ng/mL, as determined by an 
ELISA assay. 
Relaxin improves ventricular function 
Hearts were perfused in a Langendorff apparatus for optical mapping of atrial and 
ventricular action potentials to calculate conduction velocity (CV).[13,14] Aged ventricles 
treated with RLX showed a marked increase of CV, an effect that was particularly pronounced at 
fast pacing rates compared to aged control ventricles (Fig. 9Aa). CV restitution kinetics 
measured by programmed stimulation revealed that premature stimuli elicited depolarizing 
waves in control aged rats with considerably slower CV than in RLX treated aged-rats (Fig. 
9Ab). It is interesting to note that when paced at cycle lengths below 150 ms, control aged 
ventricles failed to capture and propagate or maintain a steady state CV whereas RLX-treated 
ventricles could be paced at those faster rates without significant decrement of CV (Fig. 9Aa). In 
ventricles of RLX treated rats, the slope of the restitution kinetics curve becomes less steep than 
for untreated animals which suggests a decrease in arrhythmia vulnerability (Fig. 9Ab). 
A hallmark of advancing age is an escalation of excess fibrosis. Increased collagen 
deposits are associated with cardiac dysfunction due to disruption of cell-cell coupling and a 
depolarization of the resting membrane potential.[187] Collagen content was measured by 
staining left ventricular (LV) sections with Picro-Sirius Red and by calculating the collagen to 
tissue ratio in RLX treated and control animals. RLX treatment significantly reduced the 
collagen to tissue ratio (Fig. 9Ba-c). Most important, RLX reversed age-associated fibrosis to 
levels like those measured in 11-month-old rats.[152] 
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In addition, reductions in Nav1.5 expression contribute to arrhythmia and other heart 
pathologies by slowing CV.[22] RLX significantly increased Nav1.5 expression in LV sections 
compared to control (Fig. 9Ca-c). 
Further, β-catenin was reduced in LV sections of aged (Fig. 10d) compared to adult (Fig. 
10a) rat hearts and was diffusely distributed in the cytosol with relatively little localization at 
intercalated discs (IDs) while Cx43 was localized to the lateral membranes in aged vs adult LV 
(Fig. 10e vs. 10b). RLX shifted the localization of Cx43 from the lateral membranes to IDs, 
increased the levels of β-catenin, and β-catenin became co-localized with Cx43 at IDs (Fig. 10g-
f). In general, LV of aged-rats with RLX-treatment resembled the LV of adult rats (Fig. 10a-c). 
This strongly suggested that RLX treatment reversed some of the aging-induced changes 
observed in 24-month-old rats. Similar findings were seen in aged atria (Fig. 11A). 
Relaxin acts via Wnt-signaling in aged rats 
Based on previous work of Wnt signaling effects on Nav1.5 and ID proteins, we tested 
the role of Wnt-signaling in RLX-mediated upregulation of Nav1.5 in adult and aged animals. 
RNA from aged atria ± RLX-treatment followed by RT-PCR showed the expected reduction of 
fibrosis mRNA biomarkers (Metalloproteinases (MMPs: MMP-2 and 9, α-smooth muscle actin) 
but also showed a marked increase in Wnt1 expression (Fig.11-Table). Likewise, RLX-treatment 
increased Wnt1 expression in LV sections (Fig. 11B). Next, tissue from aged LV ± RLX was 
tested for Dickkopf-1 (Dkk1) expression, an intrinsic inhibitor of Wnt signaling. Dkk1 has been 
shown to bind LRP6 and blocks canonical signaling of all Wnt ligands.[188] RLX-treated LV 
showed a significant reduction of Dkk1 compared to control LV (Fig. 12). These data suggest 
that RLX acts to activate Wnt signaling by two complementary mechanisms: increasing Wnt1 
expression and reducing Dkk1 and Wnt inhibition. 
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Figure 9: Relaxin Effects on Conduction Velocity and Collagen Expression in Aged Hearts. A: a. RLX treatment resulted in a significant 
increase in CV during steady pacing (S1:S1). b. CV restitution kinetics measured by programmed stimulation with premature pulses (S2 beats) 
was significantly increased by RLX, particularly during fast pacing times. * indicates P<0.05. 20x magnification B: LV tissue sections were 
stained with Picro-sirius red and imaged on an Olympus Provis Light Microscope. The collagen to tissue ratio was significantly reduced in RLX 
(Bb, n=6) treated animals compared to control (Ba, n=5) by 23%. C. LV tissue stained for Nav1.5 showed that RLX (Cb, n=6) significantly 
increased Nav1.5 expression compared to control hearts (Ca, n=5). 60x magnification. 
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Figure 10: Relaxin Effects on Intercalated Disk Proteins in Left Ventricle. In adult (9-months, n=4) F-344 rats (Aa-c), β-catenin and Cx43 
localized to the intercalated disks (arrows), with minimal movement of Cx43 to the lateral membranes (arrow heads). Untreated aged (24-months, 
n=4) rats (Ad-f) exhibited a marked reduction in β-catenin and translocation of Cx43 to the lateral membranes. RLX treatment (n=4) of aged 
animals (Ag-f) showed that RLX can reverse the effects of aging on β-catenin expression and results in trafficking of Cx43 to the intercalated 
disk, matching closely that seen in 9-month-old rats. Aj-k. Quantification of β-catenin/Cx43 expression. 60x magnification. 
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Figure 11: Relaxin Effects on Intercalated Disk Proteins in Atria. Aa-c. Aged right atrial tissue (Aa-c) expressed significantly less β-catenin 
and Cx43 than RLX treated animals (Ad-f). Ag-h. Quantification of atrial β-catenin and Cx43 expression (n=5/group). 60x magnification. Table 
1: Relaxin altered expression of mRNA relating to fibrotic and Wnt related genes. B. RLX (Bb) increased Wnt1 expression in LV compared to 
control (Ba). Bc. Quantification of Wnt1 expression in LV sections. 60x. 
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RLX-Wnt interaction in isolated cardiomyocytes 
The effects of RLX were studied in isolated adult left ventricular myocytes by culturing 
the cells in 96 well plates with various doses (0-100 nM) of RLX for 2-days (Fig. 13a-b). After 
treatment, the myocytes were fixed, labeled with Nav1.5 antibody and fluorescein-conjugated 
secondary antibody and fluorescent phalloidin-labeled actin used as a counterstain for 
normalization purposes. Fluorescence intensities showed that RLX up-regulated Nav1.5 with an 
EC50 of 1.3 nM (Fig 13c-e), which is consistent with the reported affinity of RLX for its cognate 
receptor, RXFP1.24 
 
 
 
Figure 12: Relaxin Effects on Dikkpof-1 Expression: Whole Left Ventricle. Relaxin significantly reduced DKK1 expression compared to 
control hearts. C = control. R = Relaxin. n = 3/group. 
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Figure 13: Relaxin Effects on Nav1.5 in Left Ventricular Cardiomyocytes. A-B: Rat ventricular myocytes treated with RLX in a graded 
manner followed by fixation and labeling with Nav1.5 Ab show that Nav1.5 fluorescence visibly increases with RLX treatment. Histogram: The 
ratio of Nav1.5 to phalloidin vs. [RLX] showed that Nav1.5 increased 3-fold at 25 nM RLX; EC50 ~ 1.3 nM, (n=6 wells/bar, P<0.01). C-D. RLX 
significantly increased Nav1.5 expression in isolated myocytes compared to control by 30% (n=10-12 cells/group). 60x magnification. 
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As shown in Figure 10, RLX increased β-catenin and Cx43 trafficking to the ID. To 
determine whether RLX also acted via a Wnt-related mechanism in isolated myocytes, we 
incubated freshly isolated ventricular myocytes with RLX (25 nM; 24-48 hours) or vehicle (Na+ 
acetate) and then double stained with DAPI (nuclear stain) and a β-catenin antibody to measure 
the number of myocytes that expressed nuclear β-catenin. Control myocytes had a considerably 
smaller fraction of β-catenin-containing nuclei (Fig. 14Aa,c) compared to RLX treated myocytes 
(Fig. 14Ab,c), suggesting that RLX is acting in part by activating canonical Wnt signaling in 
isolated cardiomyocytes. 
To determine if Wnt signaling is directly involved in Nav1.5 regulation, myocytes were 
treated with either CHIR-99021 (a GSK3β inhibitor, 3 μg/mL), RLX (25 nM) ± Dkk1 (0.1 
μg/mL) or Wnt1 (0.1 μg/mL) ± Dkk1 for 24 hours. Activation of Wnt signaling by the GSK3β 
inhibitor, CHIR-99021 resulted in a significant increase in Nav1.5 expression to the same extent 
as RLX alone and compared to control myocytes. The simultaneous treatment of myocytes with 
CHIR-99021 and RLX did not result in a further increase of Nav1.5 expression (Fig. 14Ba-e). 
Inhibition of Wnt signaling by Dkk1 significantly blocked RLX (Fig. 14f-j) and Wnt1’s (Fig 
14Bk-o) effects on Nav1.5 expression. These results strongly suggest that, contrary to the effects 
reported in NRVM, canonical Wnt signaling in adult cardiomyocytes increases Nav1.5 
expression. 
The effect of RLX on Dkk1 seen in rats treated with the hormone was also studied in 
isolated cardiomyocytes by treating the cultured myocytes with Na-acetate (control) or RLX for 
2-days followed by labeling with an anti-Dkk1 antibody. In control myocytes, Dkk1 protein 
appeared as broadly distributed punctate spots inside the cells (Fig. 15 arrows).25 In contrast, 
RLX treatment significantly reduced the expression of Dkk1 in cardiomyocytes (Fig. 15). Thus, 
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at least in part, RLX activates Wnt signaling in both cardiomyocytes and LV tissue through a 
downregulation of constitutively expressed DKK1. 
Interplay between RLX and Wnt in fibroblasts 
Fibrosis is a major contributor to impaired cardiovascular function and diastolic heart 
failure and has been shown to increase with age.[152] We have shown that RLX significantly 
reduces fibrosis in the atria [13] and ventricles of aged rats (Fig. 9). TGFβ significantly increased 
the differentiation of fibroblasts into myofibroblasts as determined by the increased levels of 
collagen I and F-actin, and RLX blocked these effects (Fig 16). The suppression of the 
differentiation of fibroblasts to myofibroblasts by RLX has been reported in neonate or 
immortalized cell lines [43,187] but these cells do not necessarily respond to RLX in the same 
manner as adult primary cardiac fibroblasts and cannot be used as evidence of the anti-fibrotic 
actions of RLX in animals. To determine the role of Wnt signaling on the effects of RLX in 
cardiac fibroblasts, adult F-344 cardiac fibroblasts were isolated, cultured with RLX and/or 
TGFβ and were treated with recombinant Dkk1 for 72 hours, after which, collagen levels were 
measured by immunofluorescence. TGFβ significantly increased collagen compared to control 
(Fig. 17a,b) and RLX blocked TGFβ’s effects (Fig. 17b). The addition of Dkk1 resulted in a 
significant reversal of the effects of RLX on collagen expression (Fig 17g). Dkk1 had no effects 
on RLX alone (Fig. 17f). These data are summarized in the bar graph shown in Fig 17d. These 
findings are consistent with RLX’s action in ventricular myocardium. Furthermore, RLX 
increased the expression of Wnt1 in cardiac fibroblasts (Fig. 18). These data strongly support our 
hypothesis: RLX increases activation of canonical Wnt signaling, and the effects of RLX on 
gene expression and TGFβ signaling are significantly inhibited by the canonical Wnt signaling 
inhibitor Dkk1. 
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Figure 14: Relaxin Signals Through Wnt Signaling to Increase Nav1.5. A. Less than 10% of untreated myocytes exhibit nuclear β-catenin 
(Aa,c); however, cells treated with RLX for 24 or 48 hours showed a significant increase in cells positive for nuclear β-catenin (Ab-c). 60x 
magnification. B. Cells treated with RLX or CHIR, an inhibitor of GSK3β and Wnt pathway activator, significantly increased Nav1.5 by more 
than 2-fold (Ba-e, n≥8 cells/group). Inhibition of canonical Wnt signaling by DKK1 blocked the effects of RLX 9 n≥24 cells/group) and Wnt1 
(n≥17 cells/group) on Nav1.5 expression (Bf-o). 60x magnification * indicates p<0.05 compared to controls. * indicates p<0.05. ** indicates 
p<0.01. *** indicates p<0.001. 
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Figure 15: Relaxin Effects on Dikkopf-1 Expression: Isolated Cardiomyocytes. Relaxin treatment for 2-days significantly reduced expression 
of DKK1 in isolated cardiomyocytes compared to control cells (n≥14 cells/group). * indicates p<0.05. 60x magnification. 
 
 
 
 
Figure 16. Relaxin Effects on Collagen Expression from Fibroblasts. Fibroblasts treated with TGFβ showed a marked increase in F-actin (top, 
n≥53 cells/group) and collagen I (bottom, n≥41 cells/group) expression that was dramatically inhibited by RLX. *indicates p<0.05. 40x 
magnification. 
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Figure 17. Relaxin-Wnt Interplay modulates Collagen Expression from Fibroblasts. Fibroblasts treated with TGFβ showed a 3-fold increase 
in collagen expression that was dramatically inhibited by RLX to 31% of control expression (a-d). DKK1 blocked RLX’s inhibitory effects of 
TGFβ mediated collagen expression (d-g); n≥43 cells/group. *indicates p<0.05 compared to control. # indicates p<0.05 compared to RLX. 40x 
magnification. 
 
 
Figure 18. Relaxin Effects on Wnt1 Expression from Fibroblasts. Relaxin significantly increased expression of Wnt1 in cardiac fibroblasts. 
*indicates p<0.05. n ≥ 46 cells/group. 40x magnification. 
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Based on intriguing clinical and pre-clinical data, RLX engendered significant 
enthusiasm as a potential therapy for cardiopulmonary diseases. In the acute heart failure trial 
RELAX-AHF, RLX treatment (30μg/kg/day for 2-days, i.v.) improved patient survival by a 
remarkable 37% in 6 months.[109] These exciting results led the FDA to declare RLX as a 
“break-through” therapy made all the more significant because the trial included patients with 
systolic and diastolic HF. Unfortunately, the reduced mortality benefits were not duplicated in a 
subsequent larger clinical trial (www.novartis.com). Detailed analysis of the larger trial has not 
been reported and the failure of RLX to significantly reduce mortality is not fully understood. A 
possible explanation is that the control group of patients receiving standard of care for HF fared 
considerably better than in earlier trials but another problem has been the design methodology of 
a 2-days treatment which has justifiably received substantial criticism.[114] Our previous studies 
on the effects of RLX in experimental animals provide compelling evidence of significant 
beneficial effects of the hormone in cardiac physiology. We reported that RLX suppressed AF in 
aged (24-months old) rats by increasing conduction velocity (CV) of atrial action potentials.[13] 
These effects were linked to increased expression of the voltage-gated sodium channel (Nav1.5) 
and current (INa), and a marked decrease in fibrosis5, both effects confirmed here in ventricles. 
At the cellular level, Relaxin was shown to upregulate INa in 24-hours but the reversal of 
fibrosis required more than a week due to the slow turn-over of collagen in the extracellular 
matrix.[14] Besides electrical and ECM remodeling, we reported that Relaxin acted as a potent 
anti-immune and anti-inflammatory agent in the ventricles of aged animals.[8] Here we examine 
the mechanisms responsible for RLX’s functions in the heart. Our results show that RLX’s 
effects are largely mediated by the modulation of canonical Wnt signaling which can act as a 
master controller of gene expression in heart and other organs. 
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This conclusion is based on several major lines of evidence: a) GSK3β inhibitors and 
exogenous Wnt1 protein mimic the effects of RLX in cardiomyocytes; b) recombinant Dkk1, a 
specific natural inhibitor of canonical Wnt signaling, blocks the effects of RLX on Nav1.5 and 
collagen I expression; c) Dkk1 expression is reduced by RLX in LV tissue and isolated 
cardiomyocytes; and d) RLX increases the expression of the Wnt1 ligand in cardiac fibroblasts. 
The integration of RLX and Wnt signaling was previously suggested by studies in prostate 
cancer18, but the mechanisms described here are very different. Whereas in prostate cancer RLX 
promotes tumor progression via its effects on the protocadherin PCDHY [184], the effects we 
described are mediated, at least in part, by increased expression of Wnt1 and reduced expression 
of Dkk1. 
Wnt signaling in the heart is complex, and different Wnt ligands have distinct effects. 
Previous studies of the actions of Wnt-signaling focused on isolated neonate rat ventricular 
myocytes (NRVM) and non-cardiac fibroblasts. In these earlier studies, treatment with Wnt1 and 
inhibition of GSK3β increased Cx43 expression and trafficking to the ID [81,84], results that are 
consistent with those reported here. The role of Wnt signaling in the regulation of Nav1.5 is 
more controversial. Liang et al. reported that incubation of NRVM with Wnt3a or CHIR-99021 
down-regulated Nav1.5 [82], results that were confirmed using the immortalized cardiomyocyte 
cell line HL-1 [182]. In contrast, findings by Asimaki et al [182], Chelko et al [84] and data 
presented here, show that canonical Wnt signaling and GSK3β inhibition increase Nav1.5 
expression in adult, aged, and diseased cardiomyocytes, suggesting that, like Wnt-signaling, 
RLX signaling is highly dependent on cell type and age. 
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5.3 Relaxin As A Therapy For PAH 
 
 
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary 
vasculature which primarily affects the small and intermediate pulmonary arterioles. PAH is the 
result of a complex pathological process which consists of elements of endothelial dysfunction, 
increased pulmonary artery contractility, proliferation and remodeling of endothelial and smooth 
muscle cells and in situ thrombosis.[189] The pathological processes lead to progressive 
narrowing of the pulmonary arterioles, resistance to blood flow and an increase in PA pressures 
resulting in pulmonary hypertension.[190] The etiology of PAH can be idiopathic, genetic, 
associated with other medical conditions, drug-induced or a consequence of pulmonary veno-
occlusive disease.  PAH is a specific classification within the broader disease of pulmonary 
hypertension which can also be secondary to left ventricular heart failure, chronic lung disease, 
chronic thromboembolic disease or other unclear/multifactorial mechanisms.[191] As PAH 
progresses, there is an increase in pulmonary vascular resistance and afterload, and the right 
ventricle (RV) begins to undergo compensatory hypertrophy and fibrosis to maintain systolic 
function and cardiac output.  Eventually, these compensatory mechanisms fail in the face of 
chronically escalating pulmonary pressures leading to RV dilation and failure.  Sudden death can 
occur in severe RV failure resulting from inadequate left ventricular (LV) filling, loss of 
systemic blood flow, followed by cardiac asystole.[190]  
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Although cardiac arrhythmias play an important role in the morbidity and mortality of 
PAH patients, [192] little is known about the arrhythmia phenotypes in the RV, especially 
compared to existing knowledge of the nature and structure of arrhythmias in LV dysfunction 
and disease.[125, 193-197] Right-sided cardiac remodeling in response to chronic pressure and 
volume overload produce an arrhythmogenic substrate in patients with PAH.  Factors 
contributing to arrhythmogenic remodeling include, modulation in autonomic activity, delayed 
cardiac repolarization and RV myocardial ischemia.[192, 198, 199] Given the paucity of data 
and understanding of RV arrhythmogenicity in PAH, we investigated the electrophysiological 
properties of the RV in an animal model of PAH. The sugen-hypoxia (SuHx) rat model of PAH 
creates sustained severe pulmonary hypertension which is accompanied by the formation of 
intrapulmonary plexiform lesions with many histopathological features of pulmonary 
arteriopathy seen in human PAH.[200, 201] Although this model recapitulates the histological 
and hemodynamic effects of PAH, it has not been characterized from an electrophysiological 
perspective.  In addition, the model offers a unique opportunity to explore the effects of putative 
therapies for PAH by measuring changes in the histology and hemodynamics of the SuHx rat.    
Relaxin (RLX) is a 53 amino acid pleiotropic hormone first characterized for its role in 
reproduction and pregnancy, but has more recently been shown to act in multiple organ systems, 
including the heart.[202] The effects of RLX on pulmonary fibrosis was previously investigated 
in rat hypoxia and murine bleomycin models of pulmonary hypertension.[61,203]  In both 
models, RLX-treatment was found to reverse pulmonary fibrosis, collagen deposition and 
alveolar thickening.[61,203]  In RLX deficient mice (RLX-/-), there is an age-dependent 
progression of lung fibrosis associated with increased tissue weight, collagen content and 
alveolar congestion which were reversed by treating RLX-/- mice with exogenous relaxin.[204] In 
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addition, relaxin has been shown to increase arterial compliance, cardiac output and renal blood 
flow.[153,205,206] Moreover, our group previously showed that RLX suppresses atrial 
fibrillation (AF) and reverses fibrosis in spontaneously hypertensive rats (SHR) [14] and in aged 
(24 months-old F-344 strain) rats.[13] Relaxin suppressed AF by increasing atrial conduction 
velocity through reversal of fibrosis and cellular hypertrophy, increasing Na+ channel expression, 
Na+ current density and connexin-43 phosphorylation. Importantly, human cardiomyocytes from 
induced pluripotent stem cells treated with RLX showed a 2-fold increase in Na+ current density.  
The beneficial cardiovascular effects of RLX formed the rationale for human trials, 
which have met with mixed results. Phase 1 and 2 trials achieved a primary endpoint of greater 
dyspnea relief but more interestingly, there was a significant decrease in mortality at 6 months, 
primarily due to reductions in stroke and sudden cardiac death, [110, 112] though a recent trial 
focused on reduced mortality failed to achieve its primary end points (https://www.novartis.com/ 
News Release of March 2017).   
Given the promising data in clinical and pre-clinical studies, we now examine the ability 
of RLX to ameliorate the deleterious cardiac effects of SuHx-induced PAH on the heart.  We 
demonstrate that RLX treatment suppressed RV arrhythmias and asystole which are typically 
observed in PAH rats. The protective effects were primarily due to an increase in CV, pulmonary 
compliance, reduction of pulmonary occlusion of pre-artery vessels and decreases in cardiac and 
inter-vascular lung fibrosis. These data suggest that RLX may improve survival of PAH patients. 
Animal Protocols  
Figure 19 summarizes the experimental protocol; starting with in situ Doppler-flow 
measurements, isolated Langendorff perfused hearts for arrhythmia phenotype measurements by 
optical mapping and ending with histology of cardiac and lung tissues.  
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Sugen-hypoxia PAH in Rats  
Rats treated with SuHX develop pulmonary arterial hypertension as evident by a 
significant increase in RV hypertrophy (Fulton Index), RV to Tibia length ratio, systolic RV 
pressure and pulmonary vascular resistance compared to controls (not shown). There were no 
significant differences in heart rate between the groups (not shown). Neither RLX LD or RLX 
HD had any significant effect on pulmonary pressure or RV hypertrophy.   (Figure 20). Flow 
Figure 19.  Experimental Protocol of Pulmonary Arterial Hypertension Study. Rats were treated with Sugen (20 mg/kg) on day 0 
and were placed in a hypobaric chamber (hypoxia: 10% oxygen) for 3-weeks then in 21% oxygen (normoxia) for another 3-weeks. Rats 
were implanted with mini-osmotic pumps to deliver Na acetate (SuHx), a low (0.03 mg/kg/day) or a high (0.4 mg/kg/day) dose of 
Relaxin. The three groups: SuHx treated rats with Na-acetate, low dose (LD) or high dose (HD) of Relaxin treatment were also 
compared to control non-PAH rats that did not receive the SuHx treatment.  At the end of the 6-weeks, pressure and Doppler flow 
catheters were used to measure hemodynamics in anesthetized rats followed by Langendorff perfusion of hearts for optical mapping of 
the arrhythmia phenotype and isolation of lung and heart tissues for histology.    
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velocity profiles in rats treated with SuHx had mid-systolic notching indicative of significant 
pulmonary vascular remodeling (Figure 20A, n=6 hearts/group). The notching pattern was 
reduced in rats treated with a high dose but not a low dose of RLX.  Heart rate did not 
significantly change among the 4 groups (Figure 20B). SuHx rats had no significant changes in 
mean velocity, stroke distance, cardiac output or stroke volume compared to controls (Figure 
20C-F). In the rats treated with RLX LD, there was a significant decrease in mean velocity, 
stroke distance, cardiac output and stroke volume compared to the rats treated with RLX HD.   
Arrhythmia Vulnerability 
After catheterization, hearts were explanted and perfused for optical mapping of APs and 
CaTs. The intrinsic heart rate was monitored under sinus rhythm followed by programmed 
stimulation to test the arrhythmia phenotype. All control hearts (n=9) were in sinus rhythm and 
no spontaneous arrhythmias or ectopic beats were noted. Simultaneous recordings of APs and 
CaTs were similar among the 4 groups (Control, SuHx, SuHx+ RLX LD and SuHx + RLX HD) 
during sinus rhythm with no observable dysfunction in CaTs (not shown). Control, SuHx and 
SuHx + RLX treated hearts underwent programmed stimulation to evaluate their arrhythmia 
vulnerability.  In control hearts, pro-arrhythmic pacing induced a sustained VF in 1 out of 9 
hearts. In SuHx PAH hearts (n=11), two types of electrical dysfunctions were observed. 1) One 
phenotype of SuHx hearts (n=4/11) had severe bradycardia relative to controls (SuHx heart rate 
was 23 ± 31 versus controls 137 ± 48 beats per minute, p=0.001) (Figure 21Ai). These hearts 
could be paced at faster rates for shorts intervals (5-10 s) and became asystolic. Electrical 
stimulation of hearts in asystole failed to capture or elicit APs and CaTs (Figure 21ii-iii). 2) The 
second phenotype of SuHx hearts had normal heart rates and spontaneous episodes of VF of 
 76 
various durations (2-50 s) (n=5/11) that progressed to sustained VF, (see supplemental movie) 
(n=3/11) (Figure 21B). 
Treatment of SuHx PAH rats with RLX LD (n=8) abrogated both types of electrical 
dysfunctions:  1) sinus bradycardia and arrest and 2) spontaneous self-terminating VF and 
sustained VF. As shown in Figure 21C, programmed stimulation with premature impulses at S1-
S2 = 85 and 70 ms (Figure 21Ci, ii) did not elicit arrhythmias and burst pacing elicited a few 
beats of transient VF (n=4/8) before recovering to sinus rhythm (Figure 21Ciii). In rats treated 
with RLX HD (n=8), programmed stimulation with S1-S2 = 60 and 55 ms failed to induce an 
arrhythmia (n=0/8; Figure 21Di-ii) and burst pacing also failed to elicit even a brief arrhythmia 
(Figure 21Diii, n=1/8). Thus, RLX HD rescued PAH hearts from bradycardia and asystole as 
well as sustained arrhythmias elicited either spontaneously, by programmed stimulation or by 
burst pacing (n=0/8). Figure 21 E and D summarize the arrhythmia phenotype observed in PAH 
hearts without and with treatments with RLX LD or HD. 
Besides RLX treatment, several pharmacological and ionic interventions were attempted 
to rescue PAH hearts from arrest. All failed except for adding dithiothreitol (DTT = 1 mM) to the 
perfusate. Figure 22A illustrates a voltage (blue) and a calcium (red) signal from a pixel on the 
RV of a PAH heart. Pacing the heart failed to elicit APs and CaTs despite testing a wide range of 
stimulation conditions and a rare spontaneous doublet of depolarization occurred which suggests 
a potentially functional RV (Figure 22A). 
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Figure 20. Relaxin/Sugen Effects on Doppler Flow Patterns. A) Representative Doppler flow velocities at the right ventricular 
outflow track show significant midsystolic notching in SuHx rats compared to controls (Ctrl). A high dose of Relaxin (+RLX HD) 
reduced the notching where there was no effect of the low dose of Relaxin (+RLX LD). B) All Doppler measurements were taken at 
similar heart rates. SuHx rats had no significant changes in C) mean Velocity, D) Stroke Distance, E) Cardiac Output or F) Stroke 
Volume compared to controls. A high dose of Relaxin significantly increased mean velocity, stroke distance, cardiac output and stroke 
volume compared to a low dose of Relaxin.      
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Figure 21. Arrhythmia Phenotypes of Pulmonary Arterial Hypertension Hearts. Optical mapping of SuHx hearts was used 
to measure RV and LV action potentials (APs) which revealed two equally prevalent phenotypes. A: SuHx hearts were in 
bradycardia (i) and could be briefly paced at higher rates (ii) which was followed by cardiac arrest (iii) (n=4/11). Once in cardiac 
arrest, electrical stimuli of various amplitude (10X threshold) and duration (1-10ms) failed to capture of elicit an AP. B: The 
other SuHx hearts exhibited spontaneous ventricular fibrillations (VF) (i) which increased in durations, were self-terminating (ii) 
and transitioned to a sustained VF, in this illustration in ~ 3 min) (iii) (n=5/11) C: Relaxin at low dose suppressed sustained VF 
and cardiac arrest (n=0/8). Panel (i) illustrates AP recordings in sinus rhythm, followed by 2 s of rapid pacing and a premature 
impulse at S1-S2 of 85 ms which failed to elicit a VF. Panel (ii) illustrates another SuHx +RLX LD heart under bradycardia, 
followed by rapid pacing and a premature impulse (S1-S2 = 70 ms). Here, the premature impulse elicits a brief transient 
arrhythmia (4 beats) and a return to sinus rhythm. Panel (iii) shows that burst pacing (4 s) elicits a transient VF that self 
terminates in < 3s). D: RLX at high dose suppressed cardiac arrest and burst pacing-induced VF Panels (i-ii) show that rapid 
pacing and premature impulses of S1-S2 = 60 or 55 ms failed to elicit VF and HD RLX suppressed al VF even after repeated 
burst-pacing events (panel (iii). E: Histogram of the 4 groups of hearts resistant to VF after rapid pacing, programmed 
stimulation and burst pacing. F: Summary of the 4 groups of hearts that exhibited transient and sustained VF or cardiac arrest.  
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Figure 22. Dithiothreitol Rescues Asystolic Pulmonary Arterial Hypertension Hearts. A: Dual optical mapping of voltage (blue) and 
Ca2+ (red) of an asystolic SuHx heart shows that the heart has no sinus rhythm and fails to capture during pacing at S1-S1 = 300 ms. A rare 
spontaneous salvo of depolarization self-terminates but the heart remains in-excitable. B: The same heart as in (A) is rescued by perfusing 
the heart with 1 mM DTT (2-3 min), as an electrical impulse successfully capture at every beat (n=2/2 hearts). C: Voltage and Calcium 
mapping of a SuHx heart in sinus rhythm illustrates spontaneous bursts of tachycardia which typically progress to sustained VF. D: 
Perfusion of the same heart with DTT (1 mM) stabilized the intrinsic sinus rhythm for the remainder of the experiment (n=2/2).  
 80 
 The same heart was then perfused with DTT (1 mM for 5 min) and electrical stimuli (300 ms 
CL) resulted in capture and propagation of APs and CaTs (Figure 22B, n=2/2). DTT rescued the 
other arrhythmogenic phenotype observed in PAH hearts. Figure 22C illustrates a PAH heart that 
exhibits spontaneous transient VF that typically progresses to sustained VF; however, perfusion 
with DTT (1 mM) suppressed these arrhythmias resulting in a recovery to a stable sinus rhythm 
(n=2/2) (Figure 22D).  
 
Conduction Velocities (CV) and Restitution Kinetics of CV  
In two models of atrial fibrillation (AF), relaxin suppressed AF in part by increasing CV 
in the atria.[22, 23] Here, CV was measured from the epicardium of the RV and LV by pacing 
each ventricle separately at 300 ms CL. The longitudinal CV of control hearts was 0.84±0.2 m/s  
in both the RV and LV (n≥4) and was markedly reduced in PAH hearts by 2.2-fold relative to 
controls (RV: 0.39±0.14 m/s, LV: 0.38±0.11 m/s; n≥4) (Figure 23A).  Low-dose of RLX 
partially reversed CVs (RV: 0.53±0.15 m/s and LV: 0.62±0.12 m/s, n≥4/group) and the RLX HD 
increased RV and LV CVs by 1.9 and 2.0-fold (n≥4). PAH hearts that received RLX HD had 
CVs that were not statistically different from control hearts (RV: 0.79±0.21 m/s, LV: 0.73±0.08 
m/s). CVs in the RVs of the RLX LD group were statistically slower than in the RV of the RLX 
HD group (p=0.02) whereas there was a trend towards slower CVs in the LVs (p=0.09). These 
data are consistent with previous findings in atria and show that RLX increases CVs in a dose-
dependent manner.    
Restitution kinetics (RK) of CV was measured by applying 20 paced impulses (S1) with 
S1-S1= 300ms followed by a single premature impulse (S2) at variable S1-S2 delays (Figure 
23B). High-dose of RLX treatment significantly improved RK of CV relative to SuHx, and RLX 
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LD improved CV but was less effective (Figure 23B). Thus, PAH results in a marked 
suppression of CV at all cycle lengths as well as the RK of CV and RLX-treatment reversed this 
arrhythmogenic effect in a dose-dependent manner. SuHx prolonged AP durations (APDs) 
measured at APD75 and RLX HD reversed APD prolongation (not shown) but these tendencies 
did not reach statistical significance. Similarly, the restitution kinetics of APD75 was not 
statistically altered in the 4 groups (not shown).   
Ventricular Remodeling  
In the SuHx model of PAH, the RV underwent a remodeling of the extracellular matrix as 
an increase in fibrosis in response to the increase in pulmonary artery pressure.  In PAH 
compared to control hearts, the collagen to tissue ratio in the RV and LV increased by 3.4 and 
3.5-fold, respectively (Figure 24A).  When SuHx rats were concomitantly treated with RLX LD, 
there was no change in RV fibrosis but a 40% decrease in LV collagen content (n≥4). When 
SuHx rats were treated with the RLX HD, RV and LV collagen were reduced 45 and 47%, 
respectively (n≥4). Representative images taken from all 4 groups from the RV and LV are 
shown in Figure 24A. Figure 24B compares the differences in fibrosis observed in the RV and 
LV in control and PAH hearts and how they were altered by RLX LD or HD, showing the RV 
contained significantly more collagen than the LV as is expected in PAH.  
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Figure 23: Relaxin Effects on Conduction Velocity in Pulmonary Arterial Hypertension. A: Plots of CV vs. cycle length 
show a 50% decrease in CV in the RV (left) and LV (right) of SuHx hearts compared to controls. RLX treatments partially 
reverse the decrease of CV in a dose-dependent manner. B: The restitution kinetics (RK) plots the CV of the premature AP as 
a function of S1-S2 inter-pulse interval.  CV RK curves of SuHx hearts have a steeper slope and are reduced compared to 
controls in the RV and LV and RLX reduces the slope of CV RK curves and increase CVs in a dose-dependent manner. * 
indicates p<0.05 vs. SuHx.  
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Figure 24: Relaxin Effects on Ventricular and Pulmonary Fibrosis. A: Top. RV collagen to tissue ratio for control, SuHx, SuHx + RLX 
LD or +RLX HD rats. Collagen to tissue ratio increased ~4-fold in SuHx compared to control rats, did not significantly change with LD RLX 
and decreased by 40% in HD RLX (n>4 per group). Bottom. LV collagen to tissue ratio for control, SuHx, SuHx +LD RLX and SuHx +HD 
RLX rats. Collagen to tissue ration increased 4-fold in SuHx compared to control and decreased by ~50% in SuHx + LD and HD RLX (n>4 
per group). Sections shown at 10x magnification, tissue stained with Mason’s Trichrome. Blue: collagen; Purple: myocardial tissue. * 
indicates p<0.05 vs. control. # indicates p<0.05 vs. SuHx.    B: Comparisons show that fibrosis was more elevated in the RV than the LV. C. 
Top panels illustrate trichrome histological sections to visualize peri-vascular fibrosis in control, SuHx, LD RLX and HD RLX treated rats. 
Analysis of bilateral lung sections (n ≥ 4 rats per group) show a ~2-fold increase in fibrosis in SuHx compared to controls, an unexplained 
small but significant increase in fibrosis with RLX LD and a 15% decrease in HD RLX compared to SuHx. Blue: collagen. * indicates p<0.05 
vs. control. # indicates p<0.05 vs. SuHx.  
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Pulmonary Vasculature  
Figure 24C shows that PAH caused the expected increase in perivascular fibrosis which 
increased by 1.6-fold (n≥4) and was not significantly lowered RLX LD whereas the RLX HD 
significantly reversed the fibrotic insult from 1.6 to 1.4-fold (n≥4).  
Based on smooth muscle actin and trichrome staining, there was respectively significant 
muscularization of the vessels and peri-vascular fibrosis in PAH (Figure 25, panel J and L) 
compared to control (panel I and K) lungs. Plexiform lesions (panel G), disintegration of the 
lamina interna (panel F) and occlusion (panel E) of small pulmonary arteries are prominently 
observed in PAH lungs and were absent in controls (panels A and B) and were moderately 
reduced in RLX-treated PAH lungs (panels C and D).   
PAH lungs had fewer ‘open’ pulmonary vessels 68% compared to 100% in controls and 
RLX (LD and HD) increased the percentage of ‘open’ vessels to 60% and 65%, respectively, 
though this did not reach significance (Figure 26A, left panel). Low and high doses of RLX-
treatment reduced the percent of partially occluded pulmonary vessels compared to untreated 
PAH rats (middle panel) and the percentage of occluded vessels in PAH lungs did not 
significantly change with RLX LD or HD (right panel). Notably in PAH patients and SuHx rats, 
intima or media fractional thickness and occlusive lesions, but not number of plexiform lesions, 
correlate with pulmonary artery pressure.[207,208]  Figure 26B shows that the percent of vessels 
with plexiform lesions was zero in controls, 8% in Su-Hx and did not significantly decrease to 
7% and 5% at RLX LD, respectively (left panel). The high-dose of RLX reduced the number of 
plexiform lesions/slide compared to untreated PAH rats (middle panel), but did not reach 
significance, and approximately the same number of vessels were examined in all 4 groups (right 
panel).[207, 209] 
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Figure 25: Histology of Diseased and Relaxin Treated Lungs. A & B: Pre-capillary pulmonary vessels in control animals. C & D: 
partially or E: completely occluded vessels in SuHx rats. F & G: early disintegration of lamina interna and plexiform lesion in G from lung 
of SuHx rat. I: minimal muscularization and K: absence of perivascular fibrosis in control rat. J: muscularization and L: perivascular 
fibrosis in SuHx rat. Verhoeff’s Van Gieson (A-H), smooth muscle-alpha actin (I, J) and trichrome (K, L) staining.  
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Figure 26. Occlusion and Plexiform Lesion Quantification of Diseased and Relaxin Treated Lungs. Quantification of occlusive and 
plexiform (PLX) lesions in male Sprague Dawley rats treated with Sugen 5416 (20mg/kg) and exposed to hypoxia for 3 weeks, followed 
by normoxia for 3 weeks (Su+Hx) or Su+Hx rats treated with relaxin. 
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In this SuHx model of pulmonary hypertension, there was a significant increase in 
systolic RV pressure with compensatory remodeling including RV hypertrophy and fibrosis. 
Optical mapping studies identified a marked decrease in CV and two striking electrical 
phenotypes in untreated PAH rats, a) bradycardia followed by cardiac arrest and b) spontaneous 
VF that were self-terminating or progressed to sustained VF. RLX-treatment produced a dose-
dependent reversal of fibrosis, increased CV and suppressed spontaneous VF or cardiac arrest. 
The effects of RLX on cardiac fibrosis and CV were previously reported in hearts from aged [13] 
and chronically hypertensive rats. [14]   
Optical mapping of PAH hearts revealed two dominant phenotypes as described above, 
but most intriguing was the robust rescue of both phenotypes by DTT which implied that these 
hearts had a compromised glutathione metabolism. Glutathione dysregulation has been 
implicated in the etiology and progression of a wide range of human diseases including heart 
failure.[210] There is mounting evidence of energy deficiency in heart failure associated with a 
disruption of oxidative phosphorylation, [211] and an augmentation of reactive oxygen species 
which readily oxidize free thiols.[212] In turn, the oxidation-reduction of reactive thiols on 
Ryanodine receptors were shown to reversibly open-close the channel [213] and was shown to 
become oxidized in ischemic [214] and failing hearts.[215]  A lower ratio of reduced to oxidized 
glutathione (GSH/GSSG) or a the loss of cytosolic GSH leads to abnormal Ca2+ handling, and 
Ca2+ alternans in a canine model of sudden cardiac death.[216]  As we showed for PAH hearts, 
restoring the redox status with exogenously added free thiols may be a promising therapy for HF. 
Likewise, RLX-treatment suppressed VF and cardiac arrest in PAH hearts most likely through a 
combination of mechanisms that may include the restoration of redox state. In further support of 
this hypothesis, preliminary RNAsequencing data in aged rats suggest a dysregulation of 
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glutathione transferase mRNA expression which is reversed by relaxin treatment, and future 
studies should study these effects in detail.    
Relaxin at the higher dose was highly cardioprotective through a reduction of cardiac 
fibrosis, an increase in AP CV and a marked suppression of VF and cardiac arrest. Doppler flow 
measurements of PAH hearts exhibited a pronounced secondary flow velocity peak indicative of 
significant pulmonary vascular remodeling which was eliminated by the high but not the low 
dose of RLX. The marked effect of high RLX dose on RV hemodynamics was aligned with a 
reduction of pulmonary peri-vascular fibrosis and a modest reduction in the number of partially 
occluded pulmonary arteries. The latter explain RLX’s lack of changes in hypertrophy and 
systolic RV pressure. The study applied a high dose of RLX based on previous studies in 
spontaneously hypertensive and aged rats but the resulting serum concentration of RLX (15 
ng/ml) did not reach the previous values (75 ng/ml) suggesting differences in biological activity 
of RLX in these models. It may well be that still higher doses might prove to be more beneficial 
particularly in terms of improving pulmonary vascular compliance. The study focused on male 
rats, yet considerable sex-differences in PAH patients and SuHx rats has been reported in regard 
to the number of plexiform lesions, with females exhibiting higher number of plexiform lesions 
than males.[33, 34] Future studies should examine sex-differences, higher concentrations of RLX 
and changes in cardiac thiol redox state in PAH hearts with and without RLX treatment.  
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6.0  Discussion 
Relaxin, a hormone discovered for its role in pregnancy, has since shown myriad 
beneficial effects in heart, liver and lung in multiple diseases including myocardial infarction, 
hypertension and aging. Despite these effects, however, there are still multiple unknowns on 
RLXs mechanisms of action. Studies have shown that, in renal fibroblasts, RLX blocks excess 
collagen expression from (myo)fibroblasts via interrupting TGFβ-SMAD signaling [43, 94] and 
involves nitric oxide-guanylyl cyclase signaling.[94] We show here that in addition to the TGFβ-
SMAD pathway, activation of Wnt signaling by RLX is also required to achieve suppression of 
fibrosis in adult primary cardiac fibroblasts. Further, there has been no work done to explain the 
mechanism of action of RLX to increase Nav1.5 to aid in arrhythmia suppression. We show that 
RLX activates canonical Wnt signaling in whole heart and in isolated cardiomyocytes, and that 
this activation is required for RLX to increase Nav1.5 expression. This action is at least partially 
achieved through increased Wnt1 and decreased DKK1 expression in LV and isolated 
cardiomyocytes. Notably, there is a lack of consensus on the effects of Wnt signaling and Nav1.5 
regulation. Studies have shown that canonical Wnt signaling can suppress [82, 182] or increase 
[124] Nav1.5 expression, and appears to be chamber specific with gain or loss of Wnt signaling 
altering Nav1.5 or showing no change depending on the heart chamber studied.[217] While it is 
unclear what is causing these discrepancies, different cell types, rodent models, age or techniques 
to activate or inhibit Wnt signaling may begin to explain them. As described in section 1.4, 
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various studies have shown that RLX can activate cAMP signaling in certain cell types, though it 
has not been determined if cAMP activation by RLX is necessary for Nav1.5 regulation. To 
explore this potential mechanism, isolated myocytes were treated with various adenylyl cyclase 
(AC), PKA and phosphodiesterase (PDE) inhibitors (not shown). The results were inconsistent 
and not reproducible with some inhibitors increasing or decreasing Nav1.5 directly and blocking 
RLX’s effects, or multiple different AC, PKA or PDE inhibitors either having no effect or 
inconsistent effects between experiments. These results lowered our confidence that RLX was 
altering Nav1.5 expression through the cAMP pathway, and led us to find a different pathway 
interaction, namely: RLX-Wnt signaling.  
Figure 27.  Relaxin Concentration in Maternal and Fetal Plasma. All maternal/fetal 
pairs displayed detectable levels of RLX in the plasma measured by ELISA.   
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Our data on RLX-Wnt signaling become increasingly significant with the understanding 
that Wnt signaling is a major driver of cardio-genesis during development.[218, 219] Earlier 
studies had suggested that the developing fetus does not receive RLX from the mother’s 
blood.[220]  However, recent preliminary work in our lab suggests that, to the contrary, there are 
detectable levels of RLX in fetal plasma (Fig. 27).  
Further, there is a strong (R2 = 0.96, p<0.05) correlation between RLX levels in the 
maternal plasma with that found in fetal plasma samples (Fig. 28), while no significant 
correlation exists between maternal or fetal RLX concentration and gestation length. While a 
limitation of this study is that we were only able to obtain maternal/fetal plasma samples 
relatively later in gestation (~32-34 weeks), this still provides compelling evidence that RLX 
may play a vital role in Wnt signaling regulation during development. This should be studied in 
detail. 
 
Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary artery 
pressure, pathological collagen deposition in the lung and occlusion of the pulmonary arterioles, 
for which there is no clinical cure. Increased pressure and pathological remodeling in PAH are 
thought to occur through an increased ratio of active vasoconstrictor molecules to 
Figure 28.  Relaxin Concentration Correlation Measurements in Maternal and Fetal Plasma. There was a strong 
positive correlation between fetal and maternal RLX plasma concentrations (left panel). There was no significant correlation 
between maternal (middle panel) or fetal (right panel) plasma concentration to gestation time.   
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vasodilators.[221-223] Based on a model of PAH induced by inhibition of the angiogenic growth 
factor, vascular endothelial growth factor (VEGF) in combination with hypoxia, which has been 
shown to induce PAH [223], we show that RLX can block the development of many of the 
pathological remodeling events that occur during PAH including: reduced RV fibrosis, increased 
action potential conduction velocity, reduced rates of arrhythmia development and inhibition of 
cardiac arrest. Further, RLX reduced plexiform lesion development and lowered the numbered of 
occluded pulmonary vessels. Interestingly, while it was shown that RLX can reduce cardiac 
arrest events, the mechanism is not clear. Using dithiothreitol (DTT), the hearts were rescued in a 
similar fashion. Since DTT is a sulfide reducing agent and had a similar effect as RLX in these 
experiments, we hypothesize that RLX may be acting as an anti-oxidant to restore energy 
imbalance that may occur in PAH. Preliminary data suggest that RLX alters the oxidative 
proteins Nrf2 and HO-1, though further work is needed in this regard. 
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7.0  Future Directions and Conclusions 
Preliminary work from our lab suggests that relaxin and Wnt signaling both mediate 
increased Nav1.5 through interplay with nitric oxide synthase (NOS). Interestingly, these effects 
do not appear to signal through the normal NOS-NO-sGC-cGMP pathway as inhibition of NOS, 
but not soluble guanylyl cyclase (sGC), blocked RLX and Wnt1 mediated increase in Nav1.5. 
While some work in cancer research [224] suggests NO can reduce DKK1 expression to activate 
Wnt signaling, there is no work in cardiac cells or tissue to confirm this, nor has this effect been 
compared in healthy and disease conditions. Further, we have studied only one ion channel 
protein, Nav1.5, in detail and it is unclear what effect relaxin-Wnt signaling interplay has on the 
various other ion channels relevant for the cardiac action potential and should be studied in detail 
in future work. 
 There are multiple avenues of study to pursue to understand RLX-Wnt mechanism of 
activation and if this effect is mediated by NO signaling. First, preliminary data from our lab 
suggests that RLX treatment of H9C2 cells leads to increased LRP6 phosphorylation, which 
could point to direct activation of canonical Wnt signaling through activation of the Wnt co-
receptor by RLX. Second, evidence suggests that β-catenin bound to eNOS [225] or E-cadherin 
[226] can be disassociated with either of these two proteins and translocate to the nucleus to 
activate Wnt signaling. Interestingly, Mei et al [226] show that this separation of β-catenin from 
E-cadherin can be mediated via MMPs, proteins known to be regulated by RLX and NO [101, 
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104]. Third, studies of RLX’s anti-fibrotic effects in renal fibroblasts suggest that RXFP1 can 
form heterodimers with the angiotensin type 2 receptor (AT2R) to mediate its effects on collagen 
suppression. [227] This contrasted with no dimer formation between RXFP1 and the thyrotropin-
releasing hormone, which was used as a control in this experiment, indicating some selectivity of 
interaction between RXFP1 and other receptors. Interestingly, they showed that while RXFP1-
AT2R dimerization was vital, RLX binding occurred only at RXFP1, with no interaction 
between RLX and AT2R directly. These data lead to intriguing ideas to study RXFP1-Fzd or 
RXFP1-LRP5/6 heterodimerization to directly activate canonical Wnt signaling to mediate 
RLX’s effect on Nav1.5 expression. Fourth, while Chow et al [227] showed that RLX did not 
directly bind to the AT2R receptor, in studies involving the glucocorticoid receptor (GR), 
Dschietzig et al [105] showed that RLX binds directly to the GR to mediate its anti-inflammatory 
effects, and that this effect was conserved in the absence of the RLX receptor. These studies 
suggest complex binding and signaling mechanisms of RLX and its receptor to other signaling 
pathways, which leads to the hypothesis that RLX/RXFP1 may be interacting directly with 
Fzd/LRP5/6 to activate canonical Wnt signaling to increase Nav1.5 expression. Further 
preliminary evidence from our lab strengthening this position, suggests that in contrast to data in 
fibroblasts which show a conserved anti-fibrotic effect of a RLX mimetic (B7-33) with the RLX 
A-chain removed [116], there is no effect on Nav1.5 expression in isolated cardiomyocytes by 
B7-33. This suggests that both chains are necessary to mediate all RLX’s effects, and that the A-
chain may be vital for RLX/RXFP1 coupling to non-RXFP1 receptors, or to activate some as yet 
unexplored signaling mechanism. 
While we have shown that Wnt signaling is necessary for RLX’s actions on Nav1.5 and 
RLX’s anti-fibrotic effects in aged myocytes and cardiac fibroblasts, respectively, the precise 
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signaling mechanisms are not clear. Data from our lab (not shown) suggest that at 48-hours of 
RLX treatment of fibroblasts, in contrast to the data seen in cardiomyocytes, there is no 
accumulation of β-catenin in the nucleus in cardiac fibroblasts. It would be useful therefore, to 
do a time-course study to determine if β-catenin accumulation in the fibroblast and myocyte 
nucleus is time or concentration dependent and how this differs between cell type.  
Similarly, studies of Wnt-TGFβ signaling interactions would be useful to determine if 
RLX mediates suppression of TGFβ signaling in a Wnt dependent manner. Further, similar 
studies as discussed in myocytes above should be performed to determine if RLX acts directly on 
Fzd or LRP5/6 to activate Wnt signaling or is acting downstream, and to determine if the 
signaling mechanism is conserved between cell type. 
Finally, and perhaps most intriguingly, preliminary ELISA data from our lab suggests 
that fetal blood receives RLX from maternal blood (Fig. 27 and Fig. 28). Given that Wnt 
signaling is highly active during development and is quiescent after birth, studies exploring 
RLX’s effects on both canonical and non-canonical Wnt signaling in embryonic and fetal tissue 
could provide breakthrough understanding on cardiovascular development during gestation and 
if RLX is a master regulator of these events during pregnancy. 
In conclusion, RLX has been shown to significantly improve cardiac action potential 
conduction through increased Nav1.5 expression, correction of cell-cell junctional protein mis-
localization and expression and reduce fibrosis. These beneficial effects of RLX appear to be 
mediated through a complex interplay between RLX-Wnt-TGFβ-NO signaling, which is largely 
unknown. Future work should include elucidation of the mechanisms of this interplay necessary 
for RLX’s effects so that effective mimetics can be produced which replicate the effects of RLX 
seen in ion channel and collagen expression modulation.  
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